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In this thesis I will describe the results of some studies conducted 
during my Ph.D regarding the exploration of some Parkinson Disease and 
Parkinsonisms’ features by mean of Dopamine transporter SPECT. SPECT 
investigation represents a valid instrument to study the extensive field of 
movement disorders giving also important information in regard to the 
pathophysiologic  pathways underlying these diseases. 
In Chapter 1 a short review on clinical application of SPECT 
methodology will explain its usefulness in the differential diagnosis of  
Movement disorders. Chapter 2 will focus on the complex regulation of the 
Dopamine transporter Proteome. In Chapter 3 and 4  the results of two 
recently published works regarding some motor and non motor aspects of 
Parkinson disease will be discussed in detail. Dementia represents a 
frequent non motor symptom with poor clinical outcome in PD but the 
pathological mechanisms are still debated. Similarly, tremor represents the 
most popular Parkinsonian symptom but also the less related to 
dopaminergic degeneration. The results of a multicenter cross over and of 
a longitudinal SPECT study in Corticobasal Syndrome will be discussed 
respectively in Chapter 5 and 6. This rare parkinsonism represents a 
challenge in movement disorder diagnostic tool and the actual clinical 
criteria have still a too low accuracy. Lastly,  chapter 7 focus on a very 
“hot topic” in functional neuroimaging studies: the preliminary results of 
an ongoing trial shows a possible interaction between FP-CIT and a new 
dopaminergic treatment with intriguing consequences in aspects such as 
neuroprotection/neurotoxicity, disease modifying  or tolerance mechanisms 
to medical treatment. 
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Chapter I 
INTRODUCTION 
DOPAMINERGIC SPECT IN PARKINSONISMS 
 
Parkinson disease (PD) is clinically diagnosed based on the presence of the 
classical motor features (in details bradykinesia, rigidity and rest tremor), 
the presence of supportive features (such as asymmetry of motor 
presentation or a good improvement to dopaminergic treatment) and the 
absence of exclusion criteria (anti-dopaminergic drugs use, vascular lesions 
in basal ganglia, tumours, etc). In most of the cases the diagnosis is 
straightforward, and no ancillary tests are required. 
A clinicopathological study published in the early 1990s found an 
accuracy of clinical diagnosis of PD of 76%. A more recent study of the 
same group in a tertiary referral centre in the UK, using ascertainment and 
methodology comparable with the previous one, has shown an 
improvement in this diagnostic accuracy, with a positive predictive value 
for those fulfilling pre-established diagnostic criteria of 90%1. Assessment 
of the clinical features suggests that an accuracy of 90% may be the highest 
that can be expected using current diagnostic criteria. Accurate 
identification of parkinsonism involving presynaptic degeneration is 
important for patient management, because the disease course, therapy and 
prognosis differ substantially from non-degenerative diseases. 
In recent years, a number of ancillary tests have been developed to 
improve diagnostic accuracy of parkinsonism with focus on early stages. 
These tests include testing for dopaminergic responsiveness using Ldopa or 
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apomorphine, autonomic function tests, brain magnetic resonance (MR), 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) imaging techniques.  
For SPECT studies, dopamine transporter (DAT) ligands (FP-CIT, 
[β-CIT, TRODAT) have become very popular. In the early 1990s, the 
cocaine analogue β-CIT has been developed and has proven to have a high 
affinity to DAT and serotonin transporter (SERT). 
Pharmacological characterisation of tracer uptake in primate brains has 
shown that striatal activity is associated mainly with DAT, whereas 
midbrain activity is mainly associated with SERT2. One of the main 
problems with the use of β-CIT is that the uptake in human striatum is 
characterised by slow kinetics, with an increase in striatal activity for 15–
20 hours after injection, which requires a delay between injection and scan 
of  24 hours. The flouropropyl derivate of β-CIT, FP-CIT has been 
developed and has proven to be selective and reliable to measure human 
brain striatal DAT with SPECT cameras3.  
FP-CIT SPECT has the main advantage of faster striatal kinetics, 
which allow imaging 3–6 h after injection. The popularity of this method in 
the differential diagnosis of Parkinson disease is explained by the exclusive 
localisation of DAT in dopamine synthesising neurons4, by a very high 
sensitivity to detect presynaptic dopaminergic dysfunction and by the 
widespread availability of SPECT scanners. 
In clinical practice, modifying factors on DAT density like gender, 
smoking and age are of low importance. One great advantage is that 
dopaminergic therapy can be continued because it has only a minor or no 
influence on DAT binding. However, dopaminergic CNS stimulants are 
known to have a significant influence on DaTSCAN and therefore need to 
be stopped prior to the scan (see Table 1). 
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Minor effect on DAT SPECT Significant effect on DAT SPECT 
Citalopram, Fluoxetine, Paroxetine, 
Venlafaxine, Duloxetine, Escitalopram, 
Fluvoxamine, Sertraline, Imipramine, 
Clomipramine, Pimozide, Ziprasidone, 
Memantine, Amantadine, Budipine, 
Ephedrine, epinephrine, Phenylephrine, 
Pseudoephedrine, Xylometazoline 
Cocaine,  Amfetamine, Methylamfetamine, 
Methylphenidate, Methylphenidate, 
Dexamfetamine, Mazindol, Phentermine, 
Modafinil, Bupropion or amfebutamone, 
Benzatropine 
 
Table 1. Relevant drug interaction with dopamine transporter single photon emission computed 
tomography (DAT-SPECT) 
 
 
1.1 PARKINSONISMS 
 
1.1.1 Parkinson disease 
Although clinical diagnosis of Parkinson disease is often straightforward 
and robust in cases with classic presentation of cardinal clinical signs and 
symptoms, 10–20% of patients diagnosed as having PD have an alternative 
diagnosis when compared with a pathological gold standard5 underlining 
the need for additional tests especially in clinically mild or uncertain cases, 
to improve diagnostic accuracy. 
Several studies have demonstrated the contribution of DAT-SPECT 
in early diagnosis of parkinsonism6-9. However, sensitivity of DAT-SPECT 
imaging to detect presynaptic dopaminergic deficit is reported to be less 
than 100%. In a study with 38 patients with a clinical diagnosis of probable 
PD according to step 1 of the UK PDS Brain Bank Criteria, Benamer and 
colleagues9 found normal FPCIT SPECT in five patients (13%) presenting 
with unilateral rest tremor and variable degrees of bradykinesia. Although 
diagnosis was changed in one patient during follow-up, 10% of clinical PD 
were not detected by DAT-SPECT imaging in this study. This number is 
also reflected in the large drug trials using DAT-SPECT or [18F]dopa PET 
imaging as a surrogate marker of disease progression where 5.7–14.7% of 
the cases clinically diagnosed as early PD had ‘‘scans without evidence of 
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dopaminergic deficit’’ (SWEEDs)10-12. Follow-up scans of those SWEDDs 
after 2 years in the REAL-PET12 study ([18F]dopa PET) and after 4 years 
in the ELLDOPA study (β-CIT SPECT) remained normal13, 14. Taking into 
account that a reduced DAT density can be observed already in preclinical 
stages (bilaterally reduced DAT density in hemi-parkinsonism6, abnormal 
DATSPECT in REM Sleep Behaviour Disorder15, and patients with an 
abnormal smell16) and that the first motor symptoms of Parkinson disease 
occur after 80% of striatal and 50% of nigral dopamine cells are lost, it is 
unlikely that DAT-SPECT, which mirrors the decline in striatal dopamine 
levels, is normal even in the early stages of Parkinson disease17. 
In a recent report, Schneider and colleagues report 12 patients with 
SWEDD who were initially diagnosed and treated as PD18. In those 
patients, DaTSCAN has been done because of atypical features (atypical 
clinical presentation, unresponsiveness to levodopa or unusual slow disease 
progression). Asymmetric tremor at rest and on action was accompanied 
with subtle signs of dystonia in most of the cases, and reduced arm swing 
or even mild hypomimia was present in some of them. It is very likely that 
the reported lack of sensitivity to detect presynaptic dopaminergic 
degeneration in PD using DAT-SPECT is mainly due to the fact that some 
patients with dystonic tremor are misdiagnosed as PD.  
DAT-SPECT has also been used as a potential biomarker for disease 
progression in PD and has shown a progressive decline of striatal DAT 
binding with the duration of PD and with increasing disease severity also in 
agreement with Fdopa PET studies19. Of interest is the lack of correlation 
between tremor scores and striatal DAT binding, whereas bradykinesia, 
rigidity as well as gait, posture, facial expression and speech explained a 
significant part of the variability in striatal FP-CIT binding20-22. In 
longitudinal studies assessing PD progression, the annual rate of reduction 
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in striatal DAT uptake is between 6 and 13% in PD patients versus 0–2.5% 
in healthy controls8, 21.  
In conclusion, DAT-SPECT is a highly sensitive (nearly 100%) 
method to detect presynaptic dopaminergic deficit in PD. A normal DAT-
SPECT in a symptomatic patient is very strong evidence against PD and 
favours alternative diagnoses than neurodegenerative parkinsonism. An 
abnormal DAT-SPECT supports the diagnosis of PD or other 
neurodegenerative parkinsonism in early disease or uncertain or incomplete 
parkinsonian syndromes. 
 
1.1.2 Inconclusive parkinsonism 
One study23 addressed the impact of DAT-SPECT on the diagnosis and 
changes in therapeutic management in patients with inconclusive 
parkinsonism (patients with uncertainty between PD and MSA or PSP were 
excluded). DAT imaging led to a change in planned management in 72% of 
cases; the most common change was the initiation of a new therapy (35%) 
and the change in follow-up appointments, and in more than half of the 
patients, diagnosis was changed after a review of the SPECT image. After 
imaging, however, patients were classified as inconclusive, which suggests 
a significant diagnostic impact of DAT-SPECT. After 2 years’ follow-up, 
DAT-SPECT images showed a high rate of agreement with clinical 
diagnosis, and the follow-up DAT-SPECT after 2 years helped to establish 
a diagnosis in 87.5% with a previously inconclusive diagnosis24. 
 
1.1.3 Genetic parkinsonism  
Patients with PARK2 (Parkin gene-related) have a more severe and more 
symmetrical loss of striatal DAT density25 but a slower progression 
compared with PD26, 27, which is in keeping with Fdopa PET findings. The 
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findings of presynaptic dopaminergic imaging described in PARK2 are 
paralleled with the findings in PARK6 (pink1- gene-related) of another 
autosomal-recessive form of young onset parkinsonism with a widespread, 
rather symmetrical and severe nigrostriatal dysfunction also present in 
asymptomatic carriers of one single mutation28. One DAT-SPECT study in 
PARK6 found presynaptic dopaminergic dysfunction similar to PD in 
patients with symptoms but normal DAT density in asymptomatic carriers 
of only one mutant gene29. Patients with symptoms with PARK7 (DJ-1 
gene-related) have also been found to have abnormal DAT imaging in the 
range of PD30. Autosomal dominant PD caused by mutations in the 
alphasynuclein gene (PARK1) as well as the much more common Lrrk2 
gene (PARK8) showed a similar degree and pattern of nigrostriatal 
dopaminergic dysfunction using Fdopa PET as found in PD31, 32. Spino-
cerebellar ataxia 2 and 3 which can present with predominant parkinsonism 
have nigro-striatal dysfunction in Fdopa PET and DAT-SPECT as seen in 
idiopathic PD33, 34. Dopa-responsive dystonia (DRD) and juvenile 
Parkinson disease (JPD) can be difficult to distinguish just on clinical 
grounds, and both have an excellent response to levodopa.  Because 
levodopa causes early and severe motor complications in JPD but not in 
DRD, it is crucial that JPD is excluded before long-term treatment with 
levodopa. In this regard, DAT-SPECT is very useful for separating these 
two conditions because it is normal in DRD35. 
 
1.1.4 Atypical parkinsonism (MSA, PSP, CBD) 
The differentiation of atypical parkinsonian disorders from PD and between 
each other can raise considerable difficulties, particularly in early disease 
stages. MSA, especially the parkinsonian subtype (MSA-P), can initially be 
very difficult to distinguish from PD before more specific symptoms like 
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pronounced autonomic involvement, laryngeal stridor or lack of response 
to dopaminergic therapy occur. The same is true for the parkinsonian type 
of PSP (PSP-P) in which the more disease specific signs and symptoms 
such as supranuclear vertical gaze palsy and imbalance with falls occur. 
Also, corticobasal degeneration (CBD) can initially easily be mistaken as 
PD because of its marked asymmetrical akinetic-rigid syndrome before 
apraxia, myoclonus and cognitive problems occur. A faster disease 
progression and a poor responsiveness to levodopa are common features in 
atypical forms and is explained by the pre- and postsynaptic dopaminergic 
degeneration. However, some responsiveness to levodopa is not uncommon 
in early MSA-P or PSP-P. It has been shown that DATSPECT is sensitive 
in detecting presynaptic nigrostriatal degeneration in PD and atypical PD 
but not useful in the differential diagnosis of PD and atypical PD36-39.  
PET and DATSPECT studies have shown that even clinically pure forms of 
MSA-C have some decrease in DAT binding but less compared with MSA-
P or PD40. This finding could be of some diagnostic impact in the 
differential diagnosis of MSA-C to idiopathic late onset cerebellar ataxia 
(ILOCA). For separating MSA from PD, other techniques such as 
combined DAT/D2 receptor SPECT can provide more information, 
although D2 receptor binding imaging methods are influenced by 
dopaminergic therapy and are therefore most useful in drug-naïve patients. 
In drug-naïve PD, D2 binding exceeds normal levels because of D2 
receptor up-regulation, whereas D2 binding is reduced in MSA early on 
because of postsynaptic degeneration. Striatal metabolic studies using FDG 
have shown to be of value in the differential diagnosis of atypical 
parkinsonism with hypermetoabolism in the dorsolateral putamen in PD, 
bilateral hypometabolism in the putamen in MSA and hypometabolism of 
the brainstem and the middle frontal cortex in PSP41. In CBD, unlike PSP 
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or PD, unilateral balanced (caudate/putamen) reduction in tracer uptake has 
been observed42.  
In conclusion, DAT-SPECT imaging does not help to differentiate between 
the neurodegenerative parkinsonian disorders. Hence, in clinical practice, 
DAT-SPECTs are not useful in differentiating between PD and atypical 
parkinsonian syndromes (MSA, PSP, CBD). 
 
1.1.5 Dementia with Lewy bodies 
In dementia with Lewy bodies (DLB), the extent of DAT loss in the 
striatum is in the range of PD43 and therefore not useful in the differential 
of PD and atypical PD. Neuropathological data suggest that 50–60% of 
dementia in people aged 65 or older is due to Alzheimer disease, with a 
further 10–20% each attributable to DLB or vascular cognitive impairment.  
Distinguishing Alzheimer disease from DLB is clinically relevant in terms 
of prognosis and appropriate treatment. A striking biological difference 
between DLB and Alzheimer disease is the severe nigrostriatal 
degeneration and consequent DAT loss that occurs in DLB, but not to any 
significant extent in Alzheimer disease44. Several imaging studies have 
shown that DAT imaging improves diagnostic accuracy with a sensitivity 
of 78% and a specificity of up to 94% in the separation between DLB and 
AD45, 46. Most of these  studies have used clinical diagnosis as the gold 
standard, and the results have to be taken with some caution. One study 
with 20 cases with pathologically proven dementias (DLB/non-DLB) and 
with an FP-CIT SPECT at initial clinical workup showed that the DAT 
imaging substantially enhanced the accuracy of diagnosis of DLB by 
comparison with clinical criteria alone47. Abnormal DAT imaging has 
therefore also been included as a suggestive feature in the DLB consensus 
criteria in 200548. 
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1.1.6 Vascular parkinsonism 
The diagnosis of vascular Parkinsonism (VP) often causes problems in the 
daily clinical work not only for general neurologists but also for movement 
disorders specialists and has remained a controversial clinical concept. The 
classical sudden-onset lower-body parkinsonism is present only in the 
minority of cases and often appears slowly progressive as seen in 
neurodegenerative causes of parkinsonism. Furthermore, vascular lesions 
are a common incidental finding in pathologically confirmed PD. Thus, a 
large proportion of patients with late onset PD have some white-matter 
changes on CT/MRI brain scans. Hence, the diagnosis of VP cannot be 
reliably confirmed on the basis of clinical features or anatomical imaging 
modalities alone, although the introduction of clinical diagnostic criteria for 
VP49 has improved diagnostic accuracy. The criteria for VP include (1) 
bradykinesia, (2) cerebrovascular disease visualised by CT or MRI and (3) 
a temporal relationship between the location of vascular lesions and the 
appearance of parkinsonian symptoms or the presence of extensive 
subcortical white-matter lesions and bilateral symptoms at onset. The value 
of DATSPECT has been explored in several studies with different results. 
One study included 20 patients with lower body parkinsonism and 
cerebrovascular disease but without lesions affecting the basal ganglia. 
Abnormal DAT-SPECT has been found in more than half of the patients50. 
Half of the patients with abnormal DAT-SPECT had a good response to 
levodopa. However, some response to levodopa does not exclude VP 
because in a series of pathologically proven VP, a substantial number had a 
good response to levodopa, especially those with lesions in or close to the 
nigrostriatal pathway51. Another study found a significantly lower 
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[123I]FP-CIT uptake compared with controls and in the range of PD52, and 
only the rather symmetrical FP-CIT uptake in VP was different to PD.  
In summary, one can conclude that a normal or mild and symmetrical 
reduction in [123I]FP-CIT uptake supports the diagnosis of VP if clinical 
criteria are fulfilled, and marked cerebrovascular disease or strategic 
infarction is present on MRI/CT. Strictly unilateral reduced uptake in the 
region of a defined vascular lesion on the MRI/CT can also be considered 
as VP. However, PD can only be excluded if DAT-SPECT is normal 
because there is considerable overlap in striatal FP-CIT uptake between VP 
and PD. 
 
1.1.7 Drug-induced parkinsonism 
Drug-induced Parkinsonism (DIP) is a common, underdiagnosed and 
serious health problem accounting for 24–35% of the causes of 
parkinsonism53 and for up to 50% of hospital admissions due to 
parkinsonism. Common offending drugs are neuroleptics and calcium-
channel blockers (flunarizine and cinnarizine). All neuroleptics, the so-
called atypical included, can cause DIP, although clozapine followed by 
quetiapine carries the lowest risk. Neuroleptics for nausea, vomiting or 
vertigo, such as prochlorperazine, thiethylperazine and metocloparmide are 
frequently responsible for DIP and commonly overlooked. 
Neuroleptic-induced parkinsonism is due to a blockade of postsynaptic D2 
receptors, whereas calcium-channel blockers and tetrabenazine have 
additional presynaptic effects. The mechanism whereby tetrabenazine 
causes only parkinsonism but not tardive dyskinesias is not entirely known. 
DIP invariably develops if more than 80% of striatal dopamine 
postsynaptic receptors are blocked54. There is evidence from patients with 
presymptomatic Parkinson disease that antidopaminergic drugs can unmask 
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PD. After withdrawal of the offending drug, there is the possibility that 
parkinsonism resolves to reoccur later on or that some parkinsonism 
persists or even worsens. DIP sometimes can be diagnosed quite easily if 
parkinsonism develops quickly after introduction of an antidopaminergic 
drug and resolves within weeks after drug withdrawal or if other movement 
disorders like oro-lingual dyskinesias, stereotypies or akathisia coexist. 
In a patient with prolonged neuroleptic therapy for psychosis who 
gradually develops parkinsonism, the question often arises as to whether 
this is true PD or whether it is DIP. In these situations DAT-SPECT can be 
particularly helpful because although neuroleptics have a marked effect on 
the brain dopaminergic system, they have a negligible affinity for DAT55, 
do not change DAT density56 and therefore have a negligible effect on 
DAT-SPECT.  
 
1.1.8 Psychogenic parkinsonism 
Psychogenic movement disorders can present with a whole variety of 
movements seen in movement disorders of organic origin (tremor, 
dystonia, chorea, bradykinesia, myoclonus, tics, athetosis, ballism, 
incoordination) and can affect speech and gait. The estimated frequency in 
movement disorders clinics is 2–3%. Psychogenic parkinsonism (PsyP) is a 
rare syndrome, accounting for 0.17–0.5% of all parkinsonism cases57, 58. 
The clinical characteristics of PsyP are atypical variable tremor, which 
lessens with distraction or concentration, in contrast with the usual 
enhancement seen in typical parkinsonian tremor. Onset is usually abrupt 
with a precipitating event, and the progression to maximum symptom 
severity and disability is usually fast. Early and accurate diagnosis is 
important to provide an adequate and potentially effective treatment but 
also to avoid unnecessary, and potentially harmful, diagnostic or 
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therapeutic procedures. Although data are limited, normal DAT-SPECT in 
PsyP is the rule, and a decreased striatal tracer uptake strongly suggests 
degenerative parkinsonism.  
 
 
1.2 TREMOR 
Tremor is a rhythmical, involuntary oscillatory movement of a one or more 
body parts and is produced by alternating and sometimes also synchronous 
contractions of agonist and antagonistic muscles. Physiological tremor has 
a frequency of  8–13 Hz on outstretched fingers and is barely visible to the 
naked eye. If the same postural tremor is easily visible but only present 
with endogenous or exogenous factors (stress, intoxication, metabolic 
factors) it is classified as enhanced physiological tremor. 
 
1.2.1 Essential tremor 
Classical essential tremor (ET) mainly affects both hands with no or only 
mild asymmetry, is classically present on posture and is not strikingly made 
worse during visually guided movements. Rarely and in more advanced 
cases, tremor can be present at rest. The tremor can also affect the chin and 
lips, neck and voice. According to the accepted definition, ‘‘essential’’ 
tremor should have no associated features. Hence, true parkinsonism or 
dystonia should not be seen in typical ET. However, some authors describe 
an association with dystonia (cervical dystonia, spasmodic dysphonia or 
writer’s cramp) in up to 47% of their patients with ET59, whereas others 
exclude patients with concomitant dystonia60. Another debate is whether 
patients with ET are at increased risk of PD. This link is supported by the 
observation that in some PD patients, a longstanding postural tremor 
precedes the onset of parkinsonism by years or even decades61 and that 
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DAT imaging was abnormal in some patients diagnosed as having ET38. 
Because different diagnostic criteria have been applied, ET is probably a 
heterogeneous disorder with differences in sex distribution, rate of 
progression and anatomic distribution of tremor as well as the associated 
features. Cases fulfilling ET criteria and without overlapping clinical 
features have invariably been found to have normal DATSPECT39. It can 
be concluded that abnormal DAT-SPECT can be considered as an 
exclusion criteria for ET. 
 
1.2.2 Dystonic tremor and tremor associated with dystonia 
According to the current MDS consensus criteria on tremor, dystonic 
tremor (DT) is defined as a low-frequency (usually less than 7 Hz) and 
low-amplitude irregular position or task-specific tremor in an extremity or 
body part that is affected by dystonia. A more heterogeneous entity is 
tremor associated with dystonia, which is defined as tremor in a body part 
not affected by dystonia, but dystonia is present elsewhere. Uni- or bilateral 
position-/action tremor of the hands is a common feature for example in 
patients with cervical dystonia. It should be recognised that patients with 
DT often have a rest tremor, sometimes even with classical pill-rolling, jaw 
tremor, facial hypomimia and impaired arm swing in the affected arm—all 
features that may suggest PD to the unwary18. In addition, some dystonia 
patients have increased limb tone (distinct from cogwheeling alone in a 
tremulous limb). This does not necessarily equate with parkinsonian 
rigidity but may be difficult to distinguish. What such patients do not have 
is true akinesia, as defined by progressive fatiguing and decrement of 
alternating repetitive movements. Patients with DT or tremor associated 
with dystonia have normal DAT-SPECT. As discussed before, DT can 
sometimes mimic PD (SWEDDs)18.  
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1.2.3 Orthostatic tremor 
Orthostatic tremor (OT) is characterised by a subjective feeling of 
unsteadiness during stance but only in severe cases during gait. No such 
problems are present when seated. Tremor is barely visible but usually 
palpable by touching the quadriceps muscle. The frequency is fast with a 
typical 13–18 Hz pattern which can be confirmed only by EMG62. One 
DAT-SPECT study of 11 patients with pure OT showed a significant 
reduction in mean striatal FP-CIT uptake in OT compared with controls63. 
A study of 41 patients with OT found that 25% had additional neurological 
features (OT-plus) such as parkinsonism, restless legs syndrome, VP or 
DIP64. One DAT-SPECT study of 11 patients with pure OT showed a 
significant reduction in mean striatal FP-CIT uptake in OT compared with 
controls63. In summary, OT is an heterogenous condition. Patients with 
pure OT may show a minor but significant reduction on DATSPECT, 
however in the individual case, in the clinical setting, images would be 
reported as normal or near normal. On the other hand, DAT-SPECT could 
be abnormal in patients with OT and additional VP or PD (OT-plus). 
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Chapter II 
INTRODUCTION 
The Dopamine Transporter 
 
PD and several other parkinsonian syndromes are characterized 
neuropathologically by degeneration of dopaminergic cells, resulting in a 
loss of dopamine transporters (DATs) in the striatum. Several radiotracers 
for positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) have been developed successfully to 
assess the integrity of presynaptic dopaminergic neurons and postsynaptic 
receptors in humans (Figure  1). 
On the presynaptic side, potential markers for imaging of the integrity of 
dopaminergic neurons are:  
 
· FDOPA (PET):  provides a measure of the structural and 
biochemical integrity of the dopaminergic neurons [3]. The 
radiotracer is taken up in the dopaminergic neuron via an amine acid 
transporter and is then decarboxylated to fluorodopamine by L-
aromatic acid decarboxylase and temporarily stored in vesicles 
within the nerve terminals.  
· 11C-DTBZ (PET): is a commonly used marker for the vesicular 
transporter [vesicular monoaminergic transporter-2 (VMAT-2)] in 
humans.  
· FP-CIT, β-CIT, TRODAT (SPECT) and  11C-PE2I, 11C-CFT 
(PET): are the most commonly DAT radioligand  
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· IBZM (SPECT), 11C-raclopride (PET), 18F-fallypride (PET): 
commonly used radiotracers for D2/3 receptors 
 
 
Figure 1. PET and SPECT ligands for pre and post-synaptic dopaminergic 
study. From Booij J and Kemp P1 
 
 
Nowadays, DAT-SPECT is used extensively in clinical practice for the 
investigation of parkinsonian patients, as well as in experimental studies, 
and it is reasonable to expect that the use of this radiotracer will increase 
even further in the near future. 
 
In the Central Nervous System the neurotransmitter DA mediates a wide 
array of physiological functions including regulation of locomotor activity, 
cognitive processes, neuroendocrine secretion, and the control of motivated 
behaviours including, emotion, affect and reward mechanisms2, 3. A key 
step that determines the intensity and duration of  DA signalling at 
synapses is re-uptake of the transmitter back into nerve terminals by the 
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plasma membrane DA transporter (DAT). Re-uptake through the DAT is 
the primary mechanism for the regulation of synaptic DA concentrations 
and thus the most effective way of terminating DA actions at postsynaptic 
and presynaptic receptors4. In addition, DAT molecules are high-affinity 
targets for cocaine and amphetamine, both of which are highly addictive 
and major substances of abuse worldwide5-7. Psycho-stimulants and 
therapeutic agents bind to the DAT, alter transporter function, and thereby 
prolong the intensity and duration of DA in the brain. 
Several proteins have been shown to interact with the DAT and 
regulate its function8-10. The DAT cannot be considered an isolated 
molecule working to pump DA inside the nerve terminal. Instead, the 
identification of interacting partners for this transporter suggests a highly 
regulated multiprotein complex formed via a coordinated network of 
protein–protein interactions. These interactions may be involved in the 
regulation of cellular processes associated with synthesis, assembly, 
targeting and trafficking, and/or may reveal novel mechanisms associated 
with the function of the transporter. 
DAT belongs to the Na+/Cl–-dependent family of neurotransmitter 
transporters, which also includes transporters for the related biogenic 
amines norepinephrine and serotonin (NET and SERT respectively), as 
well as for the inhibitory neurotransmitters GABA and glycine11. The 
topological arrangement of these transporters consists of 12 transmembrane 
domains (TMs), a large glycosylated loop between TMs 3 and 4, and 
intracellular amino and carboxy terminal domains (Figure 2).  
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Figure 2. DAT Proteome. From Torres GE22 
 
The DAT can be considered a specific marker for dopaminergic 
neurons because it is expressed exclusively in neurons that synthesize DA 
as a neurotransmitter. There is increasing evidence suggesting that the DAT 
exists as an oligomeric complex in cells. The data are consistent with a 
model in which oligomerization is necessary for the efficient exit of the 
DAT from the endoplasmic reticulum12, 13. To carry out its physiological 
role, the DAT must be targeted to specialized domains near sites of 
presynaptic DA release. DAT molecules are not located at sites where 
neurotransmitter release takes place, but are confined to peri-synaptic 
areas14, which implies that specific targeting mechanisms must exist for the 
proper localization of this transporter. DAT proteins are associated with 
intracellular compartments, particularly membranes of tubulo-vesicular 
structures and DAT molecules are strategically targeted to peri-synaptic 
sites in nerve terminals and a recycling mechanism has been postulated to 
shuttle the transporter proteins between intracellular compartments and the 
plasma membrane. 
At the cell membrane, the function of the DAT can be regulated by 
multiple second messenger systems, including protein kinase A, protein 
kinase C (PKC), protein kinase G, tyrosine kinases, phosphatases, calcium 
and calmodulin dependent kinases, and arachidonic acid16-18. The best 
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characterized effect is the down-regulation of transporter activity by PKC 
activators, which has been described extensively in several systems, 
including striatal synaptosomes and heterologous cells. PKC activation 
down-regulates the DAT by decreasing transporter Vmax with little change 
in substrate affinity. This modulation occurs largely through redistribution 
of the transporter protein at the cell surface rather than changes in intrinsic 
transport activity. More recent studies suggest that trafficking of the DAT 
can also be regulated by substrates and inhibitors of the transporter. DA 
and amphetamine induce internalization of the DAT in heterologous cells19, 
whereas cocaine increases cell surface expression of the transporter20, 21. 
Together, these results suggest that rapid DAT endocytic trafficking 
mechanisms are established at neuronal synapses.  
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Abstract – We performed 123I-FP-CIT/SPECT and ECD/SPECT in 30 
patients with Parkinson’s disease with dementia (PDD) and 30 patients 
with dementia with Lewy bodies (DLB) to evaluate whether presynaptic 
nigrostriatal function and/or cerebral perfusional pattern is different in 
these diseases. The striatal uptake of DAT tracer was statistically 
significantly lower in PDD and DLB with respect to control data (p < 
0.0005), however no significant difference was found between PDD and 
DLB. Patients with PDD and DLB showed a significant reduction of rCBF 
(p < 0.001) in parieto-occipital and frontal areas, with respect to controls, 
but the comparison between the two groups did not result in any significant 
difference by SPM analysis. Finally no correlation was found between any 
regional perfusional changes and nigro-striatal dysfunction. We conclude 
that neither studies with 123I-FP-CIT nor ECD/SPECT were able to 
discriminate between DLB and PDD in vivo. 
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1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by 
tremor, rigidity and slowness of movements. Dementia is common and 
occurs in 40–70 percent of patients with PD during the course of their 
illness1. Risk factors for dementia in PD patients include advanced age, 
treatment-induced visual hallucinations, and more severe motor 
symptoms2. The term Parkinson’s disease Dementia (PDD) refers to 
dementia that develops at least one year after the diagnosis of PD whereas 
if the cognitive impairment develops before or within one year of the onset 
of motor symptoms then the criteria are met for a diagnosis of dementia 
with Lewy bodies (DLB)3. Although clinical and neurobiologic changes are 
similar in DLB and PDD4, subtle differences have been reported. More 
executive dysfunction and more frequent psychoses have been found in 
DLB than in PDD5, as well as differences in the pattern and severity of 
parkinsonism6, and Ldopa responsivity7. Morphologic studies have 
indicated that Alzheimer-type and Lewy body pathology are more 
pronounced in DLB than in PDD8. In one study comparing structural MRI 
in DLB and PDD by means of voxel based morphometry, DLB and PDD 
differed from Alzheimer’s disease (AD) but no differences between DLB 
and PDD were shown9, whereas in a recent report despite a similar severity 
of dementia, DLB subjects had more cortical atrophy than PDD patients10.   
Several cross-sectional studies using SPECT and 123I-2b-
carbomethoxy-3b-(4-iodophenyl) tropane (b-CIT) and 123I-n-fluoropropyl- 
2b-carbomethoxy-3b-(4-iodophenyl)nor tropane (FP-CIT) demonstrated 
dopamine transporter loss in PD, PDD and DLB11, 12. Most of the 
extrapyramidal motor features of these pathologies are in fact associated 
with a progressive loss of dopaminergic neurons in the substantia nigra. 
Previous SPECT comparison studies between PD, PDD and DLB 
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demonstrated a relatively greater caudate involvement in DLB and PDD 
with respect to PD, with no differences however between such two diseases 
characterized by dementia and parkinsonism11.  
Previous studies on cerebral metabolic profiles have focused 
separately on patients with either DLB or PDD and have compared these 
patients with those suffering from AD13, 14. The few reports directly 
comparing perfusion profiles in patients with DLB and PDD using SPECT 
have shown that these diseases produce similar perfusion deficits in the 
frontal and lateral parieto-occipital regions and similar results were 
obtained in a recent study carried out with FDG PET15. However, so far no 
direct relationship between regional cerebral perfusional patterns and 
severity of nigro-striatal dopaminergic presynaptic dysfunction has been 
investigated.  
We conducted a study using SPECT and double tracer in DLB and 
PDD patients in order to test the following hypotheses:  
1. there are no significant differences between DLB and PDD regarding 
either nigro-striatal dopaminergic dysfunction or cerebral perfusional 
pattern;  
2. there are no significant correlations between changes in cerebral 
regional perfusion and nigro-striatal function as evaluated by FP-CIT 
SPECT and clinical assessment. 
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2. Patients and methods 
2.1. Patients 
We studied 60 patients (30 with PDD, 30 with DLB) referred to the 
Movement Disorders Center of Department of Neuroscience – University 
of Pisa. The diagnosis of PD was made according to UK Brain Bank 
criteria and dementia according to DSM IV whereas for DLB patients 
McKeith criteria were met3. Subjects underwent neurological and 
psychiatric examination and CT/MRI brain scan. The two groups of 
subjects were matched for sex and age (male/female PDD: 17/13; DLB: 
16/14; age: PDD 75.3±3.5; DLB 77.6±4.2). PDD differed from DLB in the 
disease duration (PDD 9.5±2.3 years; DLB 3.4±1.3 years). All patients 
were on levodopa therapy (PDD 730 mg/day±240; DLB 650 mg/day± 
330). The severity of patients’ motor impairment was assessed by Unified 
Parkinson Disease Rating Scale (UPDRS) and Hoehn–Yahr staging 
whereas cognitive functions were evaluated by a full neuropsychological 
battery and measured by the Mini Mental State Examination (MMSE). 
Twenty AD patients (9 male/11 female, age 72.3±4.9) were recruited as 
controls for the perfusional SPECT study since previous investigations 
performed with perfusional SPECT had compared DLB with AD16. Ten 
healthy elderly (4 women, 6 men, mean age 65.5±9.3 years) with MMSE 
score >27 were included in the study as controls in both SPECT studies. 
Extrapyramidal signs were excluded in the healthy control group. 
All PDD and DLB patients were on levodopa therapy and 11 PDD 
patients were taking dopamine agonists. Levodopa has been demonstrated 
not to modify FP-CIT uptake17. However all patients were off medication 
from the night before each SPECT study. No patient was taking any 
treatment known to interfere with FP-CIT SPECT scan. 
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All participants gave informant consent. The study was approved by 
the local research ethics committee. 
 
2.2. FP-CIT SPECT scanning 
SPECT studies were carried out according to standard procedure. Scanning 
took place between 3 and 4 h after the i.v. injection of 185 MBq of 123I-
FP-CIT (DaTSCAN®, GE Healthcare, UK). All subjects were scanned with 
a dual-head gamma camera (Optima NT, GE Healthcare, Milwaukee, WI, 
USA) equipped with low energy high resolution collimators (system 
resolution at 10 cm ¼ 8.3 mm). One hundred and twenty-eight projections 
for each detector were acquired on a 128 x 128 matrix (3 mm pixel size) 
over a circular 360° orbit; Radius of rotation was less than 16 cm and the 
overall scanning time for each patient was 30–45 min. Image 
reconstruction was performed by filtered back projection using a 
Butterworth prefilter (cut-off 0.4 cycles/cm, order 8); uniform Chang 
attenuation correction was applied and transaxial slices were reoriented 
along the fronto-occipital axis. 
 
2.2.1. ROI analysis 
Semiquantitative analysis was performed by using a software developed by 
GE Healthcare on a GE Xeleris workstation. The software used five 
predefined fixed ROIs which were manually positioned over the caudates, 
the putamen nuclei and the occipital cortex on reoriented axial data which 
were summed in order to obtain an overall slice of 15 mm thick, including 
almost the whole striatum nuclei. Mean counts calculated within caudate 
and putamen nuclei were divided by mean occipital counts obtaining 
striatal/to non-specific binding ratios for each nucleus. Mann–Whitney 
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signed rank U test was used in order to make the following comparisons: 
PDD group versus DLB group, PDD group versus healthy controls, DLB 
group versus healthy controls. 
 
2.3. Perfusional SPECT scanning 
On different days (at most 10 days apart) patients underwent perfusional 
SPECT. 99mTc-ethyl cysteinate dimer (Neurolite®, Bristol-Myers Squibb) 
(900 MBq) was injected with the patient lying supine in a quiet room. 
About 30 min after injection, SPECT data acquisition was carried out by 
using the same gamma camera and acquisition parameters used for FP-CIT 
SPECT. Filtered back projection with a Butterworth prefilter (0.55 
cycles/cm, order 10) was used for reconstruction, applying uniform 
attenuation correction by the Chang’s method (0.12 cm-1 attenuation 
coefficient). After reconstruction, transaxial images were reoriented along 
the fronto-occipital line and converted to DICOM 3.0 format. All 
subsequent image manipulation and data analysis were performed on a 
Windows-based computer (Microsoft, Redmond, WA). The software for 
image manipulation included the statistical parametric mapping software 
SPM2. DICOM files were converted to Analyze format to make them 
compatible with SPM by using a freeware software. Assessment of regional 
Cerebral Blood Flow (rCBF) differences between PDD, DLB and AD was 
made by SPM analysis. Finally the correlation between perfusional changes 
and nigrostriatal impairment was performed by SPM analysis using as 
covariates the striatal binding data as semi-quantitative measures obtained 
from ROI analysis and UPDRS measures (single-subject covariate model). 
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3. Results 
3.1. Subjects 
The motor impairment of the two groups (DLB and PDD) did not differ 
significantly. The mean UPDRS score in the off state was 42.3±6.2 in PDD 
patients and 39.1±5.4 in DLB group and the Hoehn–Yahr stage was 
3.1±0.9 in the PDD group and 2.9±1.1 in the DLB group. The cognitive 
profile was similar with a mean MMSE of 17.3±2.3 in PDD and 16.9±3.2 
in DLB. Twenty-four PDD patients presented with visual hallucinations 
(and 3 of them with delusions and irritability) whereas 28 DLB patients 
presented with visual hallucinations, and 7 of them delusions that were 
severe enough to require a decrease in levodopa dosage. The AD group had 
a mean MMSE of 17.9±2.1 and none of these patients had visual 
hallucinations. 
 
3.2. FP-CIT SPECT scanning 
The images obtained from patients with PDD and DLB showed a 
specific/non-specific uptake ratio significantly lower (p<0.0005) with 
respect to the control group. The statistical analysis between the two groups 
showed no significant difference as regards putamen or caudate uptake 
(right caudate DLB 1,46±0.31 vs PDD 1.59±0.22; left caudate DLB 
1.41±0.42 vs PDD 1.56±0.20; right putamen DLB 1.27±0.22 vs PDD 
1.38±0.24; left putamen DLB 1.24±0.10 vs PDD 1.33±0.23) (Figure 1 and 
2). The analysis of the index of asymmetry showed no difference between 
PDD and DLB as well as the caudate/putamen ratios data. 
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Figure 1 123FP-CIT uptake values, expressed in terms of semi-
quantitative measures as striatal/non-specific (occipital) binding ratios, in 
patients affected by Parkinson’s Disease with Dementia (PDD), Lewy 
Body Dementia (DLB) and healthy controls. *PD vs controls p < 0.005; 
**DLB vs controls p < 0.005; ***PDD vs DLB ns RC/LC: Right/Left 
Caudate RP/LP: Right/Left Putamen 
 
 
 
 
 
Figure 2 123I- FP-CIT SPECT images obtained in single cases of Lewy 
Body Dementia (DLB), Parkinson’s Disease with Dementia (PDD) and 
(right) healthy control. 
 
 
 
3.3. Perfusional SPECT scanning 
Patients with PDD and DLB showed a significant reduction of rCBF 
(p<0.001) in parieto-occipital and frontal areas with respect to controls 
(Figure 3). The comparison between the two groups did not result in any 
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significant difference. Both DLB and PDD groups when compared to AD 
group showed a significant decrease of rCBF (p<0.001) in the occipital 
regions (Figure 3). No correlation was observed between rCBF changes 
and caudate/putamen FP-CIT binding ratios as well as the UPDRS scores. 
 
 
Figure 3 MIP (maximum 
intensity projection) images 
reporting brain areas with 
significant reduction of 
rCBF (p<0.001) (top) in 
parieto-occipital and frontal 
areas in DLB and PDD with 
respect to controls, (middle) 
in occipital regions in PDD 
and DLB with respect to 
Alzheimer’s Disease (AD) 
patients, (bottom) in 
temporo-parietal regions in 
AD with respect to PDD 
and DLB. 
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4. Discussion 
In the present study significant reductions in uptake of a DAT ligand 
bilaterally in the caudate and putamen were demonstrated in patients with 
DLB and PDD compared to normal controls consistently with previous 
studies11, 12, 18. The level of dopamine transporter binding in DLB was 
indistinguishable from PDD. This finding is entirely in keeping with 
previous studies11, 12. In detail, Walker et al. found a similar impairment of 
the basal ganglia in both disorders with a symmetric loss in dopamine 
transporter more pronounced in putamen than in the caudate and more 
severe in the posterior part than in the anterior part of the putamen12. 
Similarly, in our study the loss of dopamine transporter was more 
pronounced in putamen than in the caudate and it was symmetric in both 
PDD and DLB with no significant differences. The recruitment method of 
our study population used strict criteria in order to avoid any bias due to 
potentially confounding clinical factors, in particular both the cognitive 
status and the motor impairment was very similar in both groups of 
patients. DLB and PDD are the most common dementias associated with 
deposition of Lewy bodies, and they are distinguished by a differential 
sequence of parkinsonism and dementia. Neuropathological findings 
suggest that DLB and PDD differ most in the selective vulnerability of the 
neuronal populations early in the disease process, and that cortical Lewy 
bodies along with pathological aging and Alzheimer-type pathology are the 
most common pathologic substrate for dementia in both disorders19. At 
autopsy both DLB and PDD have shown concomitant AD pathology with 
amyloid plaques and neurofibrillary tangles. Amyloid load has been 
measured in vivo with [11C]PIB PET and recent studies have shown 
indeed that the majority of DLB had PIB levels in the AD range whereas 
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most PDD patients had normal PIB uptake. These findings suggest that the 
amyloid load could contribute to an acceleration of the dementia process 
whereas Lewy body pathology alone leads to a slower dementing process 
in PDD20. Our data, confirming some diverse earlier findings, could 
suggest the lack of any difference as regards the presynaptic dopaminergic 
nigro-striatal function as assessed in vivo by FP-CIT SPECT between DLB 
and PDD. 
We found that the pattern of cerebral regional perfusion is similar 
in DLB and PDD, which is different from AD. In particular there was 
greater evidence of hypoperfusion in the lateral parts of the parieto-
occipital cortex in DLB and PDD than AD. In addition the comparison 
between DLB and PDD using a high statistical threshold did not 
demonstrate any significant difference. Parietal regions are involved in 
visuo-spatial processing, which is impaired in PD, PDD and DLB groups3 
and dysfunctions in occipito-parietal regions as assessed by in vivo 
neuroimaging in PD have been reported to well correlate with visuo-spatial 
performance21. Some authors have linked the findings of the occipito-
parietal hypoperfusion/hypometabolism to the presence of the visual 
hallucinations, but these findings are controversial. Indeed, in a post-
mortem study of patients with PD and DLB, visual hallucinations have 
been shown to correlate with Lewy bodies deposition in medial and inferior 
temporal areas including amygdala, parahippocampus and inferior temporal 
cortices whereas no correlation was found with occipital impairment22. 
Moreover, a recent FDG PET study has suggested the role of frontal 
regions in association with the hallucinations occurring in PD23. Similarly, 
in a functional MRI study, hallucinating PD patients showed an increased 
activation in the superior and inferior frontal gyrus and a decreased 
activation in regions of the posterior cortex (occipital, temporal and 
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parietal) suggesting that visual hallucinations could be due to either 
aberrant frontal signalling or to a misalignment of occipital–frontal 
circuits24. Functional abnormalities in occipital cortex remain unclear since 
structural imaging in this area in patients with PD is usually normal and the 
occipital lobe is not a major site of Lewy body pathology, although a recent 
study has shown the presence of Lewy body pathology in the secondary 
visual pathway in DLB8. Finally, occipital hypometabolism has been 
related to motor impairment in PD, since an inverse correlation between a 
motor task such as finger tapping and the metabolic pattern was reported 
suggesting an association with nigrostriatal degeneration25. On the ground 
of these evidences in the present study we have tested the presence of 
correlations between perfusional changes in any cerebral areas and both 
severity of parkinsonism as assessed by UPDRS and extent of 
dopaminergic presynaptic nigro-striatal dysfunction, as evaluated by FP-
CIT SPECT and we did not find any grade of correlation. This finding 
might further suggest that cortical hypoperfusion observed in DLB and 
PDD  could be not related to dopaminergic circuits and other subcortical 
structures are likely involved as well as different neurochemical systems. In 
this respect a link between occipital changes and visual hallucinations has 
been very recently reported by using SPECT with a cholinergic nicotinic 
ligand26, thus suggesting a negligible role for dopaminergic connections in 
the cortical perfusional alterations commonly observed in Parkinson-
Dementia spectrum. 
It should be also considered that the role of dopaminergic system 
degeneration in the development of dementia in parkinsonism is 
controversial. Some evidences have reported a greater dopaminergic cell 
loss in the substantia nigra projecting to caudate nucleus in demented than 
in non-demented patients with PD27. Indeed very recently in a non-
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demented PD population an inverse correlation was found between ventral 
caudate Fdopa uptake and several memory tasks28 and Ldopa has been 
reported to improve prospective memory in PD29. On the other hand other 
reports showing no correlation between dopaminergic impairment and 
cognitive status in PD patients30 along with the daily clinical experience 
that dementia does not improve with levodopa might support that non-
dopaminergic systems are mostly impaired with involvement of different 
cortical areas. 
 
5. Conclusion 
We conclude that neither FP-CIT nor ECD/SPECT investigations are able 
to discriminate between DLB and PDD in vivo. These findings might 
support the theory that PDD and DLB share clinical and neurobiological 
characteristics within a Parkinson – Dementia spectrum. 
Moreover, the perfusional cortical pattern of both PDD and DLB is 
unrelated to dopaminergic impairment evaluated either clinically or by 
means of 123I-FP-CIT SPECT and it may be due to different 
neurochemical systems impairment. 
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Abstract – Introduction : In idiopathic Parkinson s disease (PD), two 
different clinical phenotypes are usually distinguished: a tremor dominant 
variant (TD) and an akinetic-rigid type (ART). TD patients are 
characterized by a slower disease progression and a minor cognitive 
impairment. Striatal density of DAT, as quantified by FP-CIT SPECT, has 
been reported to correlate with rigidity and akinesia but not with tremor. 
Objective: To evaluate FP-CIT uptake in TD and ART phenotypes. 
Methods: We retrospectively evaluated from our database the pre-synaptic 
nigrostriatal function of 24 patients with TD-PD and 38 patients with ART-
PD who underwent a FP-CIT SPECT within 1 year from disease onset. 
Results: Disease duration, age at the time of SPECT scan and disease 
severity as measured with Unified Parkinson s Disease Rating scale part 
III (UPDRS III) were not statistically different between the two groups. 
Putamen contralateral to the most clinically affected side showed a lower 
FP-CIT uptake in ART patients compared to TD patients. No statistically 
significant differences emerged when considering bilateral caudate and 
ipsilateral putaminal uptake, as well as asymmetry indices and 
caudate/putamen ratios. FP-CIT contralateral putaminal uptake correlated 
with the severity of rigidity and hypokinesia but not with tremor. 
Conclusions: These data suggest that other neurotransmitter systems apart 
from the nigro-striatal dopaminergic system are involved in the generation 
of Parkinsonian tremor, and they are consistent with previous evidence of a 
lack of correlation between tremor severity and FP-CIT uptake. Putaminal 
relative sparing in TD patients could partially explain the slower disease 
progression reported in this PD phenotype. 
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1. Introduction 
 
Resting tremor, rigidity and bradykinesia are the main motor features of 
Parkinson’s disease (PD)1. It is possible to distinguish two main clinical 
subgroups, a tremor dominant (TD) and an akinetic-rigid type (ART), 
depending on the predominant motor symptoms. It has been showed that 
TD patients present a lower age at disease onset, a slower disease 
progression, less cognitive impairment and lower incidence of 
neuropsychiatric complications such as visual hallucinations and 
depression compared with ART group2, 3. 
PD is characterized by intraneuronal Lewy body inclusions, marked 
substantia nigra pars compacta dopamine neuronal loss, dopaminergic 
degeneration in putamen, caudate, globus pallidus, subthalamic nucleus and 
nucleus accumbens. The normal function in these circuits is maintained by 
nigral modulatory influence on the basal ganglia. In PD, the role of nigro-
striatal degeneration is well known, but different pallidal and striatal 
dopamine level patterns probably could underlie the two motor subgroups4. 
Thus, in TD patients, a more severe degeneration of middle part of 
substantia nigra pars compacta and lesion of retrorubral area A8 have been 
described. On the other hand, in ART group, there is a major impairment in 
the ventrolateral part of substantia nigra pars compacta5. 
[123I]FP-CIT SPECT is a sensitive means to quantify striatal density 
of dopamine transporter (DAT)6 and is currently used for clinical 
purposes7,8. It significantly correlates with the Unified Parkinson’s Disease 
Rating Scale (UPDRS) score9, Hoehn Yahr stage10 and disease duration7. 
DAT reduction significantly correlates in a linear way with severity of 
rigidity and akinesia, but not with severity of resting and postural tremor11. 
The pathophysiology of PD tremor is still currently debated, and most 
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authors support the possible involvement of other neurotransmitters such as 
serotonin, as recently also supported by imaging studies12.  
The different PD phenotypes have already been investigated with 
FP-CIT SPECT however with controversial results13, 14. The aim of this 
study was to investigate the possible differences in FP-CIT uptake between 
PD different phenotypes. 
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2. Patients and methods 
 
2.1. Patients 
Seventy-two patients with PD (mean age 64.95 years ± 12.05, M/F 39/33), 
referred to the Movement Disorders Centre of Department of Neuroscience 
– University of Pisa, were retrospectively selected from the clinical 
database. The diagnosis was reviewed according to the UK Brain Bank 
criteria. As inclusion criteria, the FP-CIT SPECT had to be performed 
within 1 year from disease onset to avoid a bias because of the disease 
progression. A diagnosis of dementia, a Mini Mental State Examination 
(MMSE) <24, the presence of orthostatic hypotension, a vertical gaze palsy 
and a poor response to dopaminergic therapy were considered as exclusion 
criteria. The definition of a SPECT as “abnormal” was performed on the 
basis of the visual inspection as previously published15. 
At the moment of the SPECT scan, 42 patients were drug naïve, 5 
patients were on Ldopa therapy, 14 were on dopamine-agonists (9 
pramipexole, 2 ropinirole, 3 cabergoline) and 11 were on combination 
therapy. Levodopa equivalent daily dosage (LEDD) was calculated as 
follows: 0.7 mg pramipexole = 5 mg ropinirole = 2 mg cabergoline = 100 
mg Ldopa16.  All patients were off medication from the night before the 
SPECT study. Dopaminergic medication has been demonstrated not to 
have a significant effect on FP-CIT uptake17,18. The patients were not 
assuming other treatment known to interfere with FP-CIT SPECT scan. 
The UPDRS section III was considered to classify our patients in the 
ART group or in the TD group. It was performed the same day of the 
SPECT study or, when it was not possible, within 1 month from the SPECT 
investigation. In any case, the examiner was always the same (C.R.), and he 
was anyway unaware of the SPECT results. In detail, we calculated a 
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tremor and an akinetic-rigid score with the method used by Lewis and 
colleagues2: the tremor score was derived by the sum of items 20 (tremor at 
rest) and 21 (postural tremor) divided by 7 (the number of single subitems 
included); the akinetic-rigid score was derived from the sum of items 18 
(speech), 19 (facial expression), 22 (rigidity), 27 (arising from chair), 28 
(posture), 29 (gait), 30 (postural stability) and 31 (body bradykinesia and 
hypokinesia) divided by 12 (the number of single subitems included). If the 
tremor score was at least twice the akinetic-rigid score, the patient was 
classified as TD; if the akinetic-rigid score was at least twice the tremor 
score, the patient was considered as ART. Thirty-eight patients were thus 
considered to have the ART, whereas 24 in the TD. The remaining 10 
patients were classified neither in the ART nor in TD and were excluded 
from FP-CIT analysis. The demographical characteristic of the two groups 
are reported in the Table 1. 
The study was approved by the Ethics Committee for Clinical 
Investigations of University of Pisa. Subjects’ consent was obtained 
according to the Declaration of Helsinki. 
 
Table 1 Demographical and clinical characteristics and FP-CIT SPECT 
measures in patients with akinetic-rigid variant (ART) and in patients 
with tremor dominant variant (TD) 
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2.2. FP-CIT SPECT scanning 
SPECT studies were carried out according to standard procedure. Scanning 
took place between 3 and 4 h after the i.v. injection of 185 MBq of 123I-
FP-CIT (DaTSCAN®; GE Healthcare, UK). All subjects were scanned with 
a dual-head gamma camera (Optima NT, GE Healthcare, Milwaukee, WI, 
USA) equipped with low energy high-resolution parallel-hole collimators 
(system resolution at 10 cm = 8.3 mm at full-width half-maximum). One 
hundred and twenty-eight projections for each detector were acquired on a 
128x128 matrix (3 mm pixel size) over a circular 360° orbit; radius of 
rotation was less than 16 cm, and the overall scanning time for each patient 
was 30–45 min. Image reconstruction was performed by filtered back 
projection using a Butterworth pre-filter (cut-off 0.4 cycles/cm, order 8); 
uniform Chang attenuation correction was applied, and transaxial slices 
were reoriented along the fronto-occipital axis. 
 
2.2.1 ROI analysis 
Semiquantitative analysis was performed using a software developed by 
GE Healthcare on a GE Xeleris workstation. The software used five pre-
defined fixed ROIs which were manually positioned over the caudates, the 
putamen nuclei and the occipital cortex on reoriented axial data which were 
summed to obtain an overall slice of 15 mm thick, including almost the 
whole striatum nuclei. Mean counts calculated within caudate and putamen 
nuclei were divided by mean occipital counts obtaining striatal/to non-
specific binding ratios for each nucleus. 
Asymmetry index (AI) in putamen, caudate and striatum was 
calculated with the following formula: AI = (ipsilateral–   
contralateral)/(ipsilateral+contralateral) x 100. A Putamen/Caudate index 
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(PCI) was calculated using the following formula: PCI = (putamen– 
caudate)/(putamen +caudate) x 10014. 
 
2.3 Statistical Analysis 
ANOVA was used for demographical data, UPDRS and MMSE. The FP-
CIT binding comparison between the two groups was obtained by Mann–
Whitney signed rank U test. Spearman s correlation coefficient was 
finally used to correlate the relationship between FP-CIT uptake and single 
UPDRS items. 
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3. Results 
 
3.1. Subjects 
Cohort characteristics in patients with TD-PD and ART-PD are 
summarized in the Table 1. The two groups do not show any statistically 
significant difference as regard disease onset, age at the time of SPECT and 
disease duration. There were no clinical differences as demonstrated by 
UPDRS section III, H&Y and MMSE scale. LEDD was similar amongst 
the two groups. 
 
3.2. FP-CIT SPECT scanning 
The average FP-CIT uptake was significantly higher in putamen of TD 
patients compared to ART, whereas there were no significant differences in 
the ipsilateral putamen, contralateral and ipsilateral whole striata and 
caudate. However, the TD group showed higher FPCIT uptake in all the 
examined regions, although not statistically significant. The asymmetry 
indices were not different between the two groups as well as the 
caudate/putamen ratios. The FP-CIT uptake values for each patient group 
are summarized in the Table 1.  
Over the 62 patients analysed, the FP-CIT uptake in contralateral 
putamen and contralateral caudate did well correlate with bradykinesia 
(putamen R = -0.693, P < 0.01; caudate R = -0.642, P < 0.01) and rigidity 
(putamen R = -0.567, P < 0.01; caudate R = 0.518, P < 0.01). Tremor items 
at UPDRS (resting and postural tremor) did not correlate with FP-CIT 
binding either in putamen or caudate (putamen R = -0.131; caudate R = 
+0.087) (see Fig. 1). 
FP-CIT uptake did not show any correlation with age and disease duration 
(P > 0.05). 
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Fig. 2. Correlation between putamen FP-CIT uptake contralateral to the 
side of disease onset and bradykinesia (a) (r = -0.693; P < 0.01), rigidity 
(b) (r = -0.567; P < 0.01) and tremor (r = -0.13). 
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4. Discussion 
 
In this study, we found a significantly higher FP-CIT uptake in 
contralateral putamen and a higher but not statistically significant uptake in 
all the other striatal regions in TD patients when compared to ART 
patients. The asymmetry indices and the caudate/putamen ratio were 
instead similar in the two different phenotypes of PD. These results were 
consistent with a previous report13 which found a greater impairment in 
ART patients in all striatal regions analysed. The different nigro-striatal 
impairment between the two clinical phenotypes might be because of a 
very early diagnosis in TD patients as long as tremor is more often 
complained by patients with respect to rigidity or bradykinesia leading 
them to a prompt neurological evaluation. However, it should be noted that 
no differences as regards disease severity as assessed by UPDRS part III, 
and H&Y scores were reported between the two subgroups, and also 
disease duration was not different in our two cohorts of patients with PD. 
To exclude any alternative diagnosis such as progressive supranuclear 
palsy, multisystemic atrophy or dementia with Lewy bodies typically 
characterized by a rigid-akinetic Parkinsonism and more severe nigral 
impairment with respect to PD, strict inclusion criteria were adopted. 
However, because these patients were seen very early despite the careful 
clinical assessment, we could not exclude once and for all other variants of 
Parkinsonism. Anyway, none of them presented atypical symptoms 
(postural instability, visual hallucinations, dementia, dysautonomia, gaze 
palsy), and all of them showed a satisfactory response to Ldopa therapy. 
Thus, the diagnosis of Parkinson’s disease is highly probable. 
By considering the homogeneity of the two subgroups and the strict 
inclusion criteria, the differences in the nigro-striatal pathways between the 
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two phenotypes are probably because of an involvement of different 
circuits. This fact could explain the different disease progression with a 
more benign course in TD group, in which a more preservation of nigro-
striatal pathway has been detected. This evidence is consistent with a more 
benign course of disease in TD with respect to ART, in which a faster 
progression as well as early motor and non-motor complications usually 
occur. 
As shown in pathological studies, ART-PD compared to the TD-PD 
is associated with a severe cell loss in the ventrolateral part of substantia 
nigra zona compacta which project to the dorsal putamen and the medial 
part projecting to caudate nucleus and anterior putamen with a negative 
correlation between substantia nigra zona compacta cell counts, severity of 
akinesia/rigidity and dopamine loss in the posterior putamen5. 
The phenotype in the early PD is not always the indicator of the 
phenotype in the evolution of the illness19, and this is a methodological 
limitation of our recruitment. However, previous studies highlight that the 
major shift was from tremor dominant to ART and only a minor shift from 
ART to tremor dominant cases19, 20. Thus, some of our tremor dominant 
patients could become ART in the following years, and this could be a bias 
in determining a less significant difference in FP-CIT uptake between the 
two groups. Therefore, the presence of significant difference in our results, 
although this bias, confirms a difference FP-CIT uptake in the two 
phenotypes.  
In the present study, FP-CIT striatal uptake values significantly 
correlate with bradykinesia and rigidity but not with tremor, as also shown 
in previous studies7, 13, 21. These findings confirm previous Fluorodopa-PET 
studies22, 23. Indeed, because UPDRS III score was not different in the two 
groups of our patients, the subscores of bradykinesia and rigidity higher in 
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ART than in TD, and more specifically related to FP-CIT uptake, probably 
result in a more compromised FPCIT striatal binding. 
Whilst resting tremor does not correlate with the nigro-striatal 
function, it probably recognizes a more complex and heterogeneous 
physiopathology compared to other cardinal symptoms. Multiple brain 
location and multiple neurotransmitter systems probably contribute to 
tremor, and the contribution of dopaminergic, cholinergic and 
serotoninergic systems can vary amongst patients. The dopaminergic role is 
well known as showed in pathological5, 24 and in imaging studies14, 25, 26. By 
means of both FP-CIT SPECT26 and Fluoro-DOPA PET23, pre-synaptic 
dopaminergic impairment was demonstrated in patients with isolated rest 
tremor. Moreover, in a recent FP-CIT SPECT study, patients with tremor 
showed a more widespread and bilateral loss of dopamine nerve terminals 
in the striatum compared to a group of PD with similar bradykinesia and 
rigidity score but without tremor14. However, the evidence of lesser 
efficacy of dopaminergic therapy on PD tremor than on other cardinal 
symptoms emphasizes the contribution of non-dopaminergic mechanisms. 
An increased metabolism in the thalamus, subthalamus, pons and pre-motor 
cortical network has been showed in patients with tremor suggesting an 
increased functional activity of thalamo-motor projections27, and recent 
evidence has found a correlation between resting tremor and serotoninergic 
impairment either in thalamus by means of SPECT and beta-CIT28 or in 
midbrain raphe nuclei as shown by PET and a tracer for the serotonin 1A-
receptor12. 
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5. Conclusion 
Our results show more severe putaminal impairment in ART patients 
compared to TD patients in agreement with slower disease progression 
reported in PD with tremor-dominant phenotype. Moreover, these data 
suggest that other neurotransmitter systems apart from the nigro-striatal 
dopaminergic system are involved in the generation of Parkinsonian 
tremor, and they are consistent with previous evidence of lack of 
correlation between tremor severity and FP-CIT uptake. 
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Abstract 
Objective: To investigate dopaminergic function in a large cohort of 
patients with corticobasal syndrome (CBS) and describe its relationship 
with clinical features in comparison to Parkinson’s disease and healthy 
control subjects. In addition, we assessed prevalence and features of 
individuals with CBS and in vivo evidence of preserved nigral neuronal 
density. 
Background: Substantia nigra pars compacta (SNc) neuronal degeneration 
is a mandatory pathological criterion for definite corticobasal 
degeneration, though sporadic autopsy-proven cases with ante-mortem 
imaging evidence of preserved nigral terminals have been recently 
described. 
Methods: In this multicenter study, we investigated presynaptic 
nigrostriatal function in 36 outpatients fulfilling clinical criteria for 
‘‘probable corticobasal degeneration’’ (age 71±7.3 years; disease 
duration 3.9±1.6 years), 37 PD and 24 healthy control subjects using FP-
CIT single photon emission computed tomography. Clinical, 
neuropsychological, and magnetic resonance imaging assessment was 
performed to characterize CBS patients. Linear discriminant analysis was 
used to categorize normal vs. pathological scans. 
Results: FP-CIT binding reduction in patients with CBS was characterized 
by larger variability, more uniform reduction throughout the striatum and 
greater hemispheric asymmetry compared to PD. Moreover, there was no 
significant correlation between tracer uptake values and clinical features 
such as disease duration and severity. Despite all CBS subjects showed 
obvious bilateral extrapyramidal signs, FP-CIT uptake was found to be 
normal bilaterally in four CBS patients and only unilaterally in other four 
cases. Extensive clinical, neuropsychological and imaging assessment did 
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not reveal remarkable differences between CBS subjects with normal vs. 
pathological FP-CIT uptake. 
Conclusions: Our findings support the hypothesis that extrapyramidal 
motor symptoms in CBS are not invariably associated with SNc neuronal 
degeneration and that supranigral factors may play a major role in several 
cases. CBS individuals with normal FP-CIT uptake do not show any 
clinical or cognitive feature suggesting a different pathology than CBD. 
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1. Introduction 
 
Corticobasal degeneration (CBD) is a progressive neurodegenerative 
disorder characterized by levodopa-resistant asymmetric akinetic-rigid 
parkinsonism and limb dystonia, variably associated with cortical features1. 
Clinicopathological studies reported a high rate of misdiagnosis in patients 
with clinical diagnosis of CBD2-9, so that it has been suggested that patients 
fulfilling clinical features of CBD should receive the clinical diagnosis of 
‘corticobasal syndrome’ (CBS), until post-mortem examination unravels 
the underlying causative pathology3, 10-12. An increasing amount of studies 
investigated clinical, neuropsychological and imaging features of patients 
with CBD-like phenotype searching for distinctive in vivo features, with 
variable and overall not conclusive results9, 13-15.  
Striatal dopamine transporter (DAT) imaging is a sensitive 
biomarker of substantia nigra pars compacta (SNc) neuronal density that 
may improve the accuracy of in vivo diagnosis in patients with CBS, given 
that SNc cell loss is a pathological finding considered to be mandatory for 
the definite diagnosis of CBD3, 16, 17. Nevertheless, ante-mortem evidences 
of preserved presynaptic nigrostriatal terminals in CBS patients who 
subsequently developed severe SNc degeneration18, 19 raise the need to 
clarify possible delayed ‘timing’ of SNc terminal loss in relation to the 
emergence of motor symptoms. 
In the present study, we investigated in vivo DAT density using 
single photon emission computed tomography (SPECT) in a large cohort of 
patients with CBS, along with extensive clinical, neuropsychological and 
brain magnetic resonance imaging (MRI) characterization. Our primary 
objective was to describe the pattern of DAT reduction in CBS compared 
to PD and healthy control subjects and to correlate DAT binding with 
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clinical features. In addition, we aimed to assess the prevalence of 
preserved SNc neuronal density in CBS population and highlight possible 
differential features between CBS subjects with normal vs. pathological 
SPECT scans. 
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2. Patients and methods 
 
2.1. Patients 
Thirty-six outpatients with clinical diagnosis of ‘probable CBD’ according 
to current diagnostic criteria1 were consecutively recruited from three 
Italian Movement Disorders Clinics (Parkinson Institute of Milan, 
Department of Neurosciences of Pisa, and Neurological Unit of Versilia 
Hospital) between 2005 and 2008. We excluded those patients with 
exposure to typical neuroleptics; those with brain MRI evidence of 
moderate-to-severe vascular abnormalities, space-occupying lesions or 
normal pressure hydrocephalus. We did not exclude patients presenting 
early cognitive impairment1, as dementia might be a presenting feature of 
CBD20. We recorded the most prominent motor and non-motor symptoms 
and signs of CBD at neurological examination1, 5 as well as presenting 
clinical features according to patients’ previous data (clinical signs were 
considered positive only if they were identified by a neurologist) or, when 
not available, as reported by the subject or caregiver as significant 
complaints. We considered as ‘early’ those features that occurred within 
the first 12 months from the clinical onset. 
Motor function assessment in CBS and PD patients included the 
Hoehn and Yahr stage (H&Y) and the Unified Parkinson Disease Rating 
Scale motor score (UPDRS III) assessed in the morning while on their 
current therapy. Twenty-six CBS patients were receiving levodopa, 12 
were taking anticholinergics and/or benzodiazepines while none was taking 
dopamine agonists, COMT or MAO-B inhibitors, amantadine, selective 
serotonin uptake inhibitors, or cholinesterase inhibitors. In the PD control 
group, individual Ldopa equivalent daily dose (LEDD) at the time of 
SPECT scan was calculated as the sum of the levodopa and dopamine 
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agonists daily dosage, as reported elsewhere21. Dopaminergic medication 
has been demonstrated not to play a significant influence on FP-CIT 
uptake22, 23. 
At the time of FP-CIT SPECT imaging, all CBS patients underwent 
full neuropsychological evaluation using the following scales: the mini 
mental state examination (MMSE)24, the Corsi block tapping test, digit 
span, story recall, frontal assessment battery (FAB)25, attentional matrices, 
verbal fluencies using category and phonemic cues (1-minute), and 
neuropsychiatric inventory (NPI)26. We applied adjustment for age and 
education when appropriate and used pathological cut-off values as 
established elsewhere27-33. We additionally recorded the occurrence of 
dementia according to Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM IV) criteria34. As CBS patients were 
assessed on-medications, we could not exclude a potential confounding 
effect of anticholinergic medications on cognitive function. We used two 
control populations to compare FP-CIT SPECT imaging binding values: 
one consisting of 37 patients with idiopathic PD according to the UK Brain 
Bank diagnostic criteria35 of similar age and disease duration and a second 
group of 32 age-matched healthy control (HC) subjects who had no history 
or evidence of neurologic or psychiatric disease. All CBS patients 
underwent 1.5 Tesla brain MRI, performed according to a previously 
published protocol36. MR images were evaluated by an independent 
neuroradiologist (unaware of the clinical and FP-CIT imaging status of 
patients) who was asked to record the following features: asymmetric or 
symmetric frontal and/or parietal cortical atrophy, diffuse cortical atrophy, 
subcortical atrophy, midbrain atrophy, normal scan. 
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The study was approved by the Ethics Committees of the institutions 
involved in the study. Subjects’ consent was obtained according to the 
Declaration Helsinki. 
 
2.2. FP-CIT SPECT 
SPECT studies were carried out either at the Nuclear Medicine, University 
of Pisa, or at the IRCCS-Ospedale Maggiore, Milan.  Intravenous 
administration of 110–185 MBq of 123I-2b-carbometoxy-3b-(4-
iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FPCIT) (DaTscanH, GE 
Healthcare) was performed 30–40 min after thyroid blockade in all subjects 
after overnight withdrawal of dopaminergic medications. Brain SPECT was 
performed 3–4 hours later by means of a dedicated triple detector gamma 
camera (Prism 3000, Philips, Eindhoven, The Netherlands) equipped with 
ultra-high-resolution fan beam collimators (four subsets of acquisitions) or 
a dual-head gamma camera (Optima NT, GE Healthcare, Milwaukee, WI, 
USA) equipped with high resolution low energy parallel holes collimators, 
matrix size 1286128, radius of rotation 13–15 cm, 120–128 projections 
over a 360° circular orbit. The overall scanning time for each patient was 
30 to 45 minutes. Brain sections were obtained by applying an iterative 
algorithm (OS-EM, 2–4 iterations and 8–15 subsets) on projection data and 
a 3D post filter (Butterworth, order 5, cut-off 0.3 Ny) and attenuation 
correction (Chang method, m = 0.12 cm21). Transaxial data were 
reoriented along the fronto-occipital line. Usually five to eight slices were 
summed in order to include the basal ganglia. Regular circular regions of 
interest were drawn on the bilateral total striatum, on the caudate nucleus 
and the putamen and used to calculate the average striatal-to-nonspecific 
uptake areas with negligible amount of dopamine receptors, such as 
occipital lobes. The formula used was as follows: FP-CIT binding = [(mean 
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radioactivity in the striatum)–(mean radioactivity in the occipital 
cortex)]/(mean radioactivity in the occipital cortex). Asymmetry indices 
(AIs) of FP-CIT binding were calculated as reported by Sherfler and 
colleagues37. The ‘contralateral’ side in CBS and PD patients was defined 
as the side opposite to the clinically most affected side. For statistical 
purposes, in healthy subjects we conventionally referred to the side with 
lower FP-CIT uptake as the ‘contralateral’. The relationship between FP-
CIT binding in the caudate nucleus and the putamen contralateral to the 
most affected body side was calculated for each individual as follows: 
Caudate-to-putamen ratio = Caudate binding/Putamen binding. Patients and 
control subjects were balanced between Milan and Pisa nuclear medicine 
departments. 
 
2.3 Data analysis 
All statistical analyses were carried out using BMDP software package for 
Windows Release 2009 (BMDP Statistical Software, University of 
California Press, Release 2009 – Berkeley, Los Angeles, Oxford). FP-CIT 
SPECT binding data (uptake values, AIs in striatum, caudate nucleus and 
putamen, and caudate-to putamen ratio) obtained from CBS patients were 
compared with those obtained from HC subjects and PD patients. 
Parametric methods were used for variables after testing for normal 
distribution (Shapiro-Wilk W statistic38). Continuous variables were 
compared using the Student’s t-tests or analysis of variance (ANOVA). For 
multiple comparisons between groups, a Bonferroni correction was applied. 
The Kruskal-Wallis test and the Mann-Whitney U test were used to 
compare variables without normal distribution. Frequencies were compared 
by means of Χ2 test, with Yates correction for 2x2 tables. In addition, 
differences in neuropsychological testing scores between the CBS patients 
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with normal vs. pathological FP-CIT uptake were calculated using 
dichotomous ‘normal’ vs. ‘pathologic’ variables, according to normative 
cut-off values. To discriminate between CBS and HC groups we performed 
linear discriminant analysis with a forward selection mechanism based on 
Wilk’s lambda as selection criteria for potential predictors, i.e. [123I] FP-
CIT mean binding values in the bilateral caudate nucleus and the putamen, 
the caudate-to putamen ratio, and the hemispheric asymmetry index of the 
striatal uptake37. An additional discriminant analysis was performed using 
caudate nuclei and putaminal uptake values as potential predictors and 
excluding indirect variables such as asymmetry indices and caudate-to-
putamen ratio. For group membership, the same a priori probability was 
assumed for all cases. For validation of the model we used a leave-one-out 
procedure. The cut-off value between two groups was determined as 
follows: (1) the mean and its confidence interval (CI 95%) of both groups 
were calculated; and (2) the cut-off value was determined by averaging 
over the lower bound of the CI of one group and the upper bound of the 
other group. In CBS and PD groups the relationship between clinical 
variables (disease duration, the UPDRS motor score, the H&Y stage, 
neuropsychological testing scores) and FP-CIT binding values in the whole 
striatum, caudate nucleus and putamen were explored using the Pearson 
correlation coefficient. Neuropsychological testing scores were correlated 
with right vs. left striatal structures rather than ispilateral vs. contralateral 
to the most affected body side.  
 
 
  74 
 
3. RESULTS 
 
Cohort characteristics in CBS, PD and HC subject groups have been 
summarized in Table 1. Compared to PD control subjects, CBS patients 
had lower LEDD (p = 0.0001) and worse disease severity (p<0.0001). 
 
 
Table 1. Demographic features and ratings in CBS, PD, and healthy 
control subjects. 
 
3.1 FP-CIT SPECT findings (Table 2, Figures 1 and 2) 
3.1.1 CBS patients vs. PD control subjects.  
When compared to PD control subjects, CBS patients showed larger 
variability in the severity and pattern of FP-CIT binding reduction, with 
more uniform reduction throughout the striatum and greater hemispheric 
asymmetry. FP-CIT uptake in CBS was similar in the striatum contralateral 
to the most affected body side and higher ipsilaterally than PD (p<0.001); it 
was lower in the contralateral caudate nucleus (p= 0.005) and similar 
ipsilaterally, higher in contralateral and ipsilateral putamen (p<0.001). 
Caudate AI was significantly higher in CBS than PD (p<0.0001), while 
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putaminal AI was similar. CBS had lower caudate-to-putamen ratio than 
PD (p<0.0001).  
 
3.1.2 CBS patients vs. HC subjects.  
CBS had reduced FP-CIT uptake and higher AIs in the caudate nucleus and 
putamen and similar caudate-to-putamen ratio in comparison to HC 
(p<0.0001 in each comparison). Using linear discriminant analysis, we 
found that thirty-two patients with CBS had pathological FP-CIT binding 
(hereafter referred to as ‘CBSP’) while four cases had normal FP-CIT 
binding (hereafter referred to as ‘CBSN’; Wilk’s Lambda = 0.075, F-
Statistic = 42.840). In the CBSP group were also included three cases (age 
62±5.5 years; disease duration 3.3±1.1 years; H&Y stage 2.5±0.5) whose 
FPCIT binding was in the normal range but whose hemispheric AI was 
significantly higher than PD control subjects (Wilk’s Lambda = 0.1653; 
cases 5, 6 and 7 in Table 3). Other four CBSP subjects had normal striatal 
uptake ipsilateral to the most affected body side but not contralaterally, 
despite bilateral extrapyramidal signs. 
 
3.1.3 CBS subgroups analysis: CBSN vs. CBSP.  
FP-CIT binding values were significantly higher in the bilateral caudate 
nucleus and putamen of CBSN compared to CBSP (p<0.001 in each 
comparison) and similar to HC subjects. Kruskall-Wallis test found 
significant differences on the mean ranks of caudate nucleus and putaminal 
FP-CIT uptake among CBSN, CBSP, PD, HC (p<0.0001). Post-hoc analysis 
showed that FP-CIT uptake in the caudate nucleus of CBSN was similar to 
HC and PD, while putaminal uptake was higher than PD (p = 0.006) and 
similar to HC, bilaterally. Striatal uptake in CBSP was similar to PD and 
lower than HC (p<0.0001). CBSP patients had higher caudate and putamen 
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AIs compared to CBSN and HC (p<0.0001 in each comparison), while they 
showed only higher caudate AI (p<0.0001) compared to PD. CBSN had 
similar caudate and putaminal AIs compared to HC, while they had similar 
caudate and lower putaminal AI (p= 0.0001) compared to PD. The mean 
caudate-to-putamen ratio was similar in CBSN vs. CSBP vs. HC, while this 
was higher in PD than all the other groups (p<0.001 in each comparison). 
 
 
 
 
Table 2. Semiquantitative FP-CIT binding values in caudate nucleus and 
putamen, hemispheric asymmetry indices and caudateto-putamen ratio in 
CBS, PD, and healthy control subjects. 
 
 
 
Fig. 1. Scatter plot showing individual FP-CIT uptake values in the 
striatum contralateral and ipsilateral to the most affected body side in 
CBS, PD, and HC subjects. The uptake values of HC subjects have been 
averaged between the two sides. The line represents the mean. 
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Fig. 2. Scatter plots showing hemispheric asymmetry indices in the total 
striatum, caudate nucleus and putamen in CBSN, CBSP, PD, and HC 
subjects. 
 
3.2 Clinical, neuropsychological and brain MRI features 
In the whole group of CBS patients (n= 36), extrapyramidal signs were 
similarly recorded in 94% of cases in the early stages of the disease, 
irrespective of FP-CIT uptake. Patients presented with either akinetic 
(92%), dystonic (11%), apraxic (67%) arm, or gait disorder/postural 
instability (30%) (Table 3). During the disease course, all patients 
developed full-blown typical clinical picture of CBS and none experienced 
significant and sustained clinical improvement from chronic levodopa 
treatment. Disease duration was negatively correlated with FP-CIT uptake 
in the striatum, the caudate nucleus and the putamen only in PD (p<0.01 in 
all the analyses) but not in CBS (Figure 3A). This difference remained 
significant also after excluding CBSN subjects from the analysis (data not 
shown). H&Y stage negatively correlated with striatal FPCIT binding in 
the PD group (p<0.01) while showed a trend for negative correlation with 
striatal binding in CBS patients (Figure 3B). The UPDRS motor score 
showed negative correlation with striatal uptake in PD (p<0.01) and CBS 
(p = 0.047) groups. Neuropsychological profile of the whole CBS cohort 
was overall characterized by mildly reduced global cognitive performance, 
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characterized by reduced frontal lobe functions and relatively preserved 
verbal and visuospatial short and long-term memory tasks (Table 4).  We 
did not find any correlation between FP-CIT binding and any of the 
neuropsychological scores. We applied non-parametric tests to investigate 
the differences between CBSN and CBSP (Table 3). Demographic and 
general clinical features were similar between the two CBS subgroups, with 
the exception of mean longer disease duration in CBSN at the time of 
SPECT (p= 0.038). Clinical presentation did not significantly differ 
between the two CBS subgroups, with the only exception of early memory 
impairment, that was more frequently reported in the clinical history of 
CBSN patients (p<0.005). At the time of SPECT scan, CBSP patients had 
higher prevalence of postural instability and falls than CBSN (p= 0.005) 
while parietal lobe signs other than apraxia were more frequently reported 
in CBSN vs. CBSP (p<0.001). Neuropsychological testing scores did not 
differ between CBSN and CBSP (Table 4). Brain MRI findings were not 
different between CBSN vs. CBSP (Table 5). Finally, statistical analyses 
performed lumping together all CBS patients showing normal FP-CIT 
uptake values (n= 7 subjects, Table 6) confirmed the lack of any significant 
difference between CBSN vs. CBSP in all the clinical, neuropsychological 
and MRI variables investigated, including disease duration (4.962.3 vs. 
3.761.4, p = 0.08). 
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Table 3. Clinical signs of CBSN and CBSP at the time of FP-CIT 
SPECT. Features are reported as number of patients (%) within each 
subgroup. Extrapyramidal signs refer to the combination of bradykinesia 
and rigidity. Yates corrected Χ2 test was applied, *p,0.005. 
 
 
Table 4. Neuropsychological testing of CBS patients with normal (CBSN) 
and pathological (CBSP) FP-CIT uptake. Values have been adjusted for 
age and education and given as mean (SD). 
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Fig. 3. Correlation of FP-CIT binding in the contralateral striatum. 
Shown with the disease duration (A), and disease severity, according to 
the H&Y stage (B), in CBS patients and in PD controls. 
 
 
Table 5. Brain MRI features of all CBS patients (CSBtot) and the two 
subgroups of those with normal (CBSN) and pathological (CBSP) FP-CIT 
uptake values. Features are reported as N° of patients (%). Intergroup 
differences were calculated by Yates corrected Χ2 test. 
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Clinical features Case 1 Case 2 Case 3 Case 4 (Case 5) (Case 6) (Case 7) 
Gender F M F M F M F 
Age at onset 77 64 74 58 67 62 56 
Age at SPECT 81 72 78 66 71 64 60 
Disease duration at FP-CIT SPECT 4 8 4 8 4 2 4 
Levodopa daily dosage 750 0 0 0 400 300 300 
Hoehn and Yahr stage 3 4 2,5 2,5 2,5 2 3 
UPDRS III 37 38 25 25 32 22 30 
Language dominant hemisphere L L L L L L L 
Clinical presentation 
 
Gait difficulty. 
Cognitive impairment. 
 
Hand clumsiness 
and jerk  tremor, 
gait difficulty 
Depression. 
 
Hand 
clumsiness, 
rigidity and tremor. 
Episodes of 
disorientation 
/confusion 
 
Hand 
clumsiness 
and rigidity. 
 
Hand clumsiness, 
gait difficulty. 
 
Language production 
and behavioral 
disturbances. 
Hand clumsiness. 
 
Hand clumsiness, 
gait difficulty, 
bradykinesia. 
 
Motor signs 
       
Side of motor symptoms onset R L L R L L L  
Akinesia (+)  (+)  (+)  (+)  (+) (+)  (+) 
Rigidity (+)  +  (+)  (+)  (+) (+)  (+) 
Tremor - (+) (+) + - + (+) 
Limb dystonia / Clenched fist + / + + / + (+) / + + / + + / - - / - + / - 
Myoclonus  - + + + - + (+) 
Gait disturbance (+) (+) - - (+) - (+) 
Postural instability  - - - - - - + 
        
 
Cortical/cognitive features 
       
Dementia (+) + (+) - - + + 
Limb apraxia + (+)  (+) + (+) + + 
Alien limb phenomenon  + + - + + + + 
Cortical sensory deficit + + + + - - - 
Non-fluent aphasia + + + + - (+) (+) 
Early memory impairment - - + - - - + 
Early visuo-spatial dysfunction + + + - - + + 
Behavioral abnormalities/personality changes - - - - - (+) + 
Other features        
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Dysarthria and/or Dysphagia - + - + + - - 
Oculomotor impairment - + - - + + - 
Depression (+) (+) - + (+) + (+) 
Frontal-lobe release signs + + + - + + + 
Other frontal/parietal lobe signs Gait apraxia Left-sided   Left-sided  Right-sided  - - Gait apraxia 
  neglect,  neglect,  neglect    
  gait apraxia  prosopagnosis.     
 
Neuropsychological testing 
       
MMSE 16 20 13 28.9 23.7 17.9 18 
Corsi Block Tapping Test 2.5 2 2 4 4.75 2.25 2.11 
Digit Span 4 4.4 5 4.75 3.75 3.5 3.5 
Story recall  7.5 5 4.3 8.2 13.8 8.8 n.a. 
Attentional Matrices 13.5 15 26 33 31.5 11.5 n.a. 
Category Verbal Fluency n.a. 17 14 24 n.a. n.a. n.a. 
Phonemic Verbal Fluency 8 13 18 14 13 10.9 7.2 
Frontal Assessment Battery 6 7 9 12.9 11.8 10 5 
Neuropsychiatric Inventory 20 15 12 14 6 16 18 
 
 
       
FP-CIT SPECT binding         
Contralateral striatum  1,78 1,53 1,49 1,48 1,72 1,66 1,92 
Ipsilateral striatum  1,65 1,71 1,56 1,48 2,07 1,72 2,04 
Contralateral caudate  1,60 1,77 1,72 1,54 1,73 1,50 2,08 
Ipsilateral caudate  1,47 1,87 1,75 1,57 2,36 1,78 2,48 
Contralaterale putamen  1,87 1,51 1,57 1,58 1,65 1,74 1,84 
Ipsilaterale putamen  1,82 1,57 1,60 1,57 1,90 1,68 2,06 
Asymmetry index (Striatum) 7,30 10,53 4,49 0,00 16,91 3,49 5,88 
Asymmetry index (Caudate nucleus) -8,84 5,35 1,71 1,91 26,69 15,73 16,13 
Asymmetry index (Putamen) -2,75 3,82 1,88 -0,64 13,16 -3,57 10,68 
Caudate:Putamen ratio 0,86 1,17 1,10 0,97 1,05 0,86 1,13 
 
Table 6. Demographic features, clinical signs and ratings, FP-CIT uptake measures and additional neuroimaging investigations in the 4 CBS patients with 
normal FP-CIT measures. 
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4. Discussion 
 
This is the first study investigating presynaptic dopaminergic function 
along with extensive clinical and neuropsychological characterization in a 
large cohort of patients fulfilling clinical criteria for ‘probable CBD’. The 
primary outcome of this study was to describe the pattern of striatal FP-CIT 
uptake reduction in CBS and correlate FP-CIT binding with clinical 
features. Compared to PD control subjects, individuals with CBS showed a 
large FP-CIT binding variability in terms of overall striatal binding as well 
as hemispheric asymmetry and caudate-to-putamen ratio (Figures 1 and 
2). In consistence with typical CBD pathological features17, we found 
higher hemispheric asymmetry in caudate nucleus and putaminal FP-CIT 
uptake together with a more uniform reduction within striatal regions in 
CBS, thus reflecting the highly asymmetrical involvement and SNc 
neuronal loss involving both dorsal and ventral tiers in CBD16, 17 in contrast 
to PD, where cell loss is typically confined to SNc ventral tiers39. These 
features well explain the difference in the caudate-to-putamen ratio of FP-
CIT uptake between the two disorders. When correlation analysis was 
performed between nigrostriatal function and clinical features in CBS, FP-
CIT binding showed did not show any correlation with disease duration and 
just a trend with disease severity, while this association was highly 
significant in PD control subjects (Figure 3A and B). Previous imaging 
studies already highlighted a less pronounced SNc neuronal loss in patients 
with CBS compared not only to severe atypical parkinsonian syndromes 
(such as progressive supranuclear palsy and multiple system atrophy) but 
also to idiopathic PD40-44. Interestingly, some CBS patients had 
symmetrical FP-CIT reduction despite strongly asymmetrical symptoms, a 
finding already described in a previous Fluorodopa-PET study41. A recent 
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description of autopsy proven CBD with ante-mortem evidence of 
preserved presynaptic nigrostriatal terminals suggested a possible delayed 
timing of SNc cell degeneration, unrelated to the onset of motor 
symptoms18, 19. The lack of relationship between FP-CIT binding and 
disease duration and the very weak correlation with disease severity we 
found in our CBS cohort is in line with this hypothesis. Moreover, the 
presence of obvious bilateral symptoms but evidence of reduced DAT 
density only unilaterally in some CBS cases would further suggest that SNc 
pathology may require a variable time to occur bilaterally. These findings 
highlight a mismatch between SNc neuronal loss and clinical features (such 
as asymmetry of motor symptoms, disease duration and severity) and 
support the hypothesis of a prominent role played by cortical and/or striatal 
pathology in the clinical picture of this syndrome. The lack of any 
correlation between FP-CIT binding and cognitive performance is an 
expected finding that is consistent with ‘cortical’ rather than ‘subcortical’ 
pathology underlying cognitive deficits in CBS compared to PD. 
As secondary objective, we aimed to assess the prevalence and 
characterize those CBS subjects with normal FP-CIT scans aiming to find 
any distinctive clinical or neuropsychological feature. To achieve this 
objective, we used very restrictive a priori criteria to minimize false 
positive cases and found preserved SNc neuronal density in approximately 
10% of our cases. So far, normal dopamine transporter density has been 
reported only sporadically in CBS19, 45, while none of the few systematic 
imaging studies in consecutive cohorts ever documented any normal scan40-
44. To our knowledge, there are only few reports of patients with clinical 
diagnosis of CBD with preserved SNc neuronal density at post-mortem, 
and most of them displayed either Alzheimer’s or Pick’s disease 
pathology2, 3, 5, 7, 9, 10, 14, 15, 46-48. The first possible explanation would come 
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from a possible pathological involvement of the downstream postsynaptic 
neurons, even though the pathological involvement of postsynaptic striatal 
neurons in CBD is variable and unpredictable17, 49. A second hypothesis 
would posit that extrapyramidal symptoms in CBS with normal SNc 
density might be associated with frontal and/or parietal cortical rather than 
striatal pathology4, 7, 19, 50, 51. In the attempt to rule this out, we extensively 
investigated clinical, neuropsychological and MR imaging features of our 
CBS cohort and did not find any major clue suggesting an alternative 
diagnosis than CBD. Although early memory impairment was more 
frequently recorded in the history of CBSN cases (Table 3), full 
neuropsychological assessment revealed similar features in both subgroups, 
including preserved memory functions, consistent with the pattern shown 
in definite CBD (Table 4)52. Notably, our cohort is representative of 
specialized movement disorders centres so that the number of cases 
presenting with prominent cognitive impairment and mild-to absent 
extrapyramidal symptoms is relatively low, as these subjects would rather 
refer to third-level dementia clinics20, 52. SNc depigmentation is less evident 
in CBD cases presenting with severe cognitive symptoms53 and it is thus 
conceivable that we underestimated the real prevalence of normal FP-CIT 
scans in CBS population6, 20. Moreover, CBS subjects with normal scans 
showed a mean longer disease duration than CBS patients with presynaptic 
nigrostriatal degeneration despite similar degrees of motor disability, 
suggesting a more indolent course.  
We acknowledge that the interpretation of our findings is limited by 
the lack of pathological confirmation of the diagnosis. Indeed, some CBS 
patients with normal FP-CIT binding might still turn out to be focal cortical 
variants of other dementia than CBD3, 7, 10, 46, 47, 54–59, because clinical 
features and the distribution of pathological lesions are closely associated 
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whatever the histologic nature3, 4, 9, 14. Post-mortem assessment in CBS 
cases with preserved SNc neuronal density could also unravel the 
pathological underpinnings of extrapyramidal symptoms. A second 
limitation in the interpretation of the comparison between CBSN and CBSP 
comes from the marked unbalance in the number of cases between the two 
groups.  
Taken as a whole, our findings support the hypothesis of a mismatch 
between SNc neuronal loss and clinical features with a variable 
contribution played by supranigral pathology in extrapyramidal phenotype. 
We speculate that the well-known heterogeneity of CBD pathology60 might 
additionally include variants with predominant involvement of the cerebral 
cortex and disease progression in the rostro-caudal direction to the 
brainstem, in a kind of ‘cortico-to-basal’ progression of neuronal 
degeneration. This hypothesis is supported by pathological studies showing 
a less evident SNc depigmentation in CBD cases presenting with cognitive 
rather than motor symptoms53 and already demonstrated in Lewy bodies 
dementia61, 62. Clinicopathological studies including in vivo DAT imaging 
are needed to assess the predictive value of normal presynaptic nigrostriatal 
function in the diagnostic work up of patients with CBD-like phenotype. 
 
 
5. Conclusion 
In vivo assessment of dopamine transporter SPECT imaging in a large CBS 
population was found to be normal in about 10% of cases despite 
prominent bilateral extrapyramidal signs. In these cases, clinical and 
neuropsychological features were not distinct from those with evidence of 
SNc neuronal loss. The lack of any correlation between presynaptic 
nigrostriatal dysfunction and disease duration might suggest an 
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unpredictable and possibly delayed SNc degeneration in CBD and further 
supports the hypothesis of a variable contribution of supranigral pathology 
to its motor phenotype. 
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Abstract 
Objective: To demonstrate that degeneration of substantia nigra neurons 
may occur at later stages of disease in some patients with corticobasal 
syndrome (CBS) who evidenced preserved nigrostriatal pathway at a 
baseline FP-CIT SPECT study. 
Background: Current pathological criteria for the definite diagnosis of 
corticobasal degeneration consider substantia nigra cell loss as a 
mandatory finding. However, dopamine transporter SPECT imaging 
performed in a large cohort of CBS patients showed about 10% of normal 
scans. 
Methods: We describe 4 patients with clinical diagnosis of CBS and normal 
FP-CIT SPECT at baseline whose tracer uptake resulted to be pathological 
at 1-year follow-up scan. Clinical assessment has been performed at the 
time of SPECT scan. A semi-quantitative approach was performed for 
striatal FP-CIT binding values. 
Results: Baseline SPECT scans have been performed after 2.3±1.5 years 
from onset. All CBS patients presented asymmetric rigid-akinetic 
parkinsonism (mean Hoehn-Yahr stage 2.5; UPDRS motor score 18) with 
poor levodopa response and ideo-motor limb apraxia. At follow-up, 
neurological examination revealed some additional features, including 
limb dystonia, language impairment, postural instability, ocular gaze 
impairment, alien limb. All patients showed pathological FP-CIT uptake at 
the SPECT performed 10-15 months apart from the baseline scan.  
Conclusions: Our longitudinal FP-CIT SPECT findings support in vivo the 
hypothesis that substantia nigra neuronal loss may occur at later stages in 
some patients with CBS, despite early extrapyramidal symptoms. 
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1. Introduction 
 
Substantia nigra pars compacta (SNc) neuronal loss is a 
neuropathological finding that is mandatory for the definite diagnosis of 
corticobasal degeneration (CBD)1. However, a large variability in SNc 
neuronal density reduction not correlating with clinical features and up to 
10% of cases preserved nigrostriatal function have been recently reported 
in a large cohort of patients with clinical diagnosis of corticobasal 
syndrome (CBS)2, 3. Taken together with  an autopsy-proven CBD patient 
with  in vivo evidence of normal presynaptic nigrostriatal function but post-
mortem evidence of severe SNpc neuronal death few years later4, these 
findings would suggest a possible delayed timing of nigral cell death in 
some CBD cases.  
In consistence with this hypothesis, we herewith describe four 
patients with clinical CBS2 who had normal tracer binding at the FP-CIT 
SPECT performed at the time of the first evaluation and whose follow-up 
SPECT assessment revealed significant SNpc neuronal loss. 
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2. Patients and methods 
 
2.1. Patients 
The 4 consecutive patients were consecutively recruited at the 
Movement Disorder Centre – University of Pisa – Italy. All patients were 
longitudinally evaluated and underwent to a follow up FP-CIT SPECT after 
10-15 months.  The patients were not the same collected in our previous 
study3 because two of them were lost at follow up and the other two refused 
to perform a SPECT scan because of the severity of illness.  
The study was approved by the Ethics Committees of the institutions 
involved in the study. Subjects’ consent was obtained according to the 
Declaration of Helsinki. 
 
2.2. FP-CIT SPECT 
SPECT studies were carried out either according to standard procedure3. 
Scanning took place between 3 and 4 hours after the e.v. injection of 110-
185 MBq of 123I-FP-CIT (DaTSCAN®, GE Healthcare, UK) in all 
subjects after overnight withdrawal of dopaminergic medications.  
Three subjects (cases 1 to 3) were scanned with a dual-head gamma 
camera (Optima NT, GE Healthcare, Milwaukee, WI, USA) equipped with 
high resolution low energy parallel hole collimators. A fourth patient was 
scanned with a triple detector gamma camera (Prisma 3000, Philips, 
Eindhoven, The Netherlands) equipped with ultra-high-resolution fan beam 
collimators (four subsets of acquisitions). 120-128 projections for each 
detector were acquired on a 128x 128 matrix (3mm pixel size) over a 
circular 360° orbit; radius of rotation was 13-15 cm and the overall 
scanning time for each patient was 30 to 45 minutes. SPECT imaging 
conditions were kept unchanged between baseline and follow-up scans for 
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all patients, including scanner, tracer doses and adequate wash-out of drugs 
potentially interfering with tracer uptake. 
Brain sections were obtained by applying an iterative algorithm (OS-
EM, 2–4 iterations and 8–15 subsets) on projection data and a 3D postfilter 
(Butterworth, order 5, cut-off 0.3 Ny) and attenuation correction (Chang 
method, µ = 0.12 cm-1). 
 
2.3 ROI analysis  
Transaxial data were reoriented along the fronto-occipital line. Usually five 
to eight slices were summed in order to include the basal ganglia. Regular 
circular regions of interest were drawn on the bilateral total striatum, on the 
caudate nucleus and the putamen and used to calculate the average striatal-
to-nonspecific uptake areas with negligible amount of dopamine receptors, 
such as occipital lobes.  The formula used was as follows: FP-CIT binding 
= [(mean radioactivity in the striatum)-(mean radioactivity in the occipital 
cortex)]/(mean radioactivity in the occipital cortex). Asymmetry indices 
(AIs) of FP-CIT binding and the Caudate-to-putamen ratio were calculated 
as reported elsewhere5. The ‘contralateral’ side was defined as the 
hemisphere opposite to the clinically most affected side. 
FP-CIT SPECT was defined as ‘pathological’ when tracer uptake values 
were at least 2 SD below the mean values of healthy control subjects6. 
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3. RESULTS 
 
Case series  
Clinical and FP-CIT SPECT binding values have been summarized in 
Table 1 and 2, respectively. 
 
Case 1 - A 61 year-old woman presented with a 4-year history of language 
impairment (speech apraxia), focal facial twitching, left upper limb rigidity 
and bradykinesia, associated with apraxia. Cognitive assessment revealed 
poor performance at the clock drawing test and frontal-lobe dysfunction. 
Brain MRI evidenced bilateral cortical parietal atrophy, while FDG-PET 
showed right-sided parietal cortical hypometabolism. FP-CIT SPECT 
performed at this time was normal. At 9-month follow-up, she showed oro-
lingual apraxia along with facial twitching, severe dysarthria and 
worsening of aphasia. Frontal-lobe release signs were present on the left 
side. One-year follow-up FP-CIT SPECT showed a significant bilateral 
reduction of striatal uptake, mainly on the right side. 
 
Case 2 - A 73 year-old man with 1-year history of progressive gait 
disturbances and postural instability presented with asymmetric rigid-
akinetic right-sided parkinsonism, associated with dystonia and mild jerky 
tremor of the upper limb.  Neuropsychological assessment showed  
language impairment (aphasia) and ideomotor apraxia on the right hand. 
Neuroimaging showed left fronto-parietal atrophy (brain MRI) and 
hypometabolism (FDG-PET). Nigrostriatal function was preserved at FP-
CIT SPECT. At 10-month follow-up, the patient showed a clear-cut 
worsening of parkinsonism along with the appearance of upper limbs 
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myoclonus and vertical ocular gaze impairment. Follow up SPECT scan 
showed significant tracer reduction in the bilateral  striatum. 
 
Case 3 - A 75 year-old man referred for a 10-month history of progressive 
right upper limb clumsiness and walking difficulties presented cogwheel 
rigidity and hyperreflexia, myoclonic jerks and dystonia in the right arm. 
Brain MRI showed left-sided fronto-parietal cortical atrophy and FDG-PET 
frontal lobe and basal ganglia hypometabolism bilaterally. Mild language 
and memory impairment and a moderate ideo-motor apraxia were also 
present. Baseline FP-CIT SPECT (15 months from the onset) was normal 
as  it was also second SPECT scan performed 9 months later. Over the next 
few months, his gait and right-sided parkinsonism got worse and he 
developed vertical ocular gaze impairment with slow saccadic movements. 
A third FP-CIT SPECT (30 months from the onset) showed significant 
tracer binding reduction on the left striatum.        
 
Case 4 - A 68 year-old female with a 3-year history rigidity and 
bradykinesia of left arm and gait difficulties presented left-sided 
parkinsonism with mild ideomotor apraxia of left hand and gait 
disturbance. At that time FP-CIT SPECT was normal. Her symptoms 
progressively worsened over the next 12 months, with the appearance of 
dysarthria, left hand dystonia, vertical oculomotor impairment, postural 
instability, apathy and frontal-lobe release signs. At the follow-up, FP-CIT 
SPECT showed significant binding reduction at both striata. 
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Case 1 Case 2 Case 3 Case 4  
Baseline Follow up Baseline Follow up Baseline Follow up* Baseline Follow up 
Gender  F M M F 
Age at the SPECT (ys) 61 62 73 74 75 77 68 69 
Disease Duration (ys) 4 5 1 2 1 3 3 4 
UPDRS III 9 14 20 32 22 45 41 58 
Hoehn and Yahr stage 2 2.5 3 3 3 4 2 3 
Symptoms at onset Language disturbance Gait disturbance and postural instability 
Right clumsiness and gait 
impairment  Left bradykinesia 
Levodopa response / Negative / Negative / Negative / Negative 
Postural instability No No Yes Yes Yes Yes No Yes 
Dystonia No No Yes Yes Yes Yes No Yes 
Tremor/Myoclonus Facial myoclonus  Jerky tremor Myoclonus Myoclonus Myoclonus Tremor Tremor 
Alien limb No No No No No No No No 
Dysarthria/Dysphagia No Dysarthria No Dysarthria No Dysarthria Ipophonia Dysphagia 
Ocular movement Normal Normal Normal Impaired Normal Impaired Normal Impaired 
Limb apraxia Yes Yes Yes Yes No Yes Yes Yes 
Memory impairment No No No No Yes Yes No - 
Attention impairment Yes Yes Yes Yes Yes Yes Yes - 
Visuo-spatial 
dysfunction Yes Yes No No No No No - 
Language impairment Yes Yes Yes Yes Yes Tes Yes - 
Apathy/depression Mild depression Depression No No No Depression 
Mild 
depression - 
MMSE - - 25 25 24 23 25 24 
Table 1. Demographic, clinical and Neuropsychological features. *Clinical and neuropsychological features refer to the third SPECT examination 
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CASE 1 CASE 2 CASE 3 CASE 4  
Basel. Post Basel Post Basel Post Basel Post 
Controls 
Ipsilateral Putamen 1.81 1.19 1.73 1.18 1.75 1.16 1.77 1.14 1.68 (0.1) 
Contralateral Putamen  1.77 1.12 1.69 1.11 1.70 1.09 1.72 1.07 1.71 (0.2) 
Ipsilateral Caudate 1.78 1.28 1.79 1.32 1.88 1.42 1.85 1.35 1.77 (0.2) 
Contralateral Caudate 1.85 1.34 1.75 1.26 1.81 1.35 1.79 1.28 1.82 (0.2) 
Caudate-to-Putamen ratio 1.05 1.22 1.04 1.22 1.07 1.14 1.05 1.21 1.07 (0.1) 
Asymmetry Index Caudate 3.79 4.46 2.21 4.52 3.72 4.91 3.24 5.18 5.28 (3.3) 
Asymetry Index Putamen 2.20 5.90 2.29 5.95 2.83 6.03 2.82 6.14 3.8 (2.3) 
 
Table 2. Baseline and follow up FP-CIT SPECT uptake in the cohort of CBD patients 
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4. Discussion 
 
This case series confirms that presynaptic nigrostriatal dopaminergic 
function in patients with clinical diagnosis of CBS might be preserved 
despite obvious signs of parkinsonism showing a progressive delayed 
reduction even after several years from the onset4.  
All our 4 patients with a normal dopamine transporter (DAT) density 
at the baseline SPECT fell into reduced levels at the follow up SPECT. 
Only “Case 3” presented a preserved dopaminergic function at the follow 
up SPECT performed after 9 months. However a third SPECT evaluation 
showed pathological levels of DAT density in this patient too. In 
consideration to this small cohort we can’t give any information regarding 
to a subgroup of patients with normal SPECT throughout all the clinical 
history but it is presumably reasonable that a proportion of CBS patients 
presents a preservation of SNc, in agreement with several pathological 
studies7-9. In our study there is a probable bias in patients selection due to 
the fact that diagnosis was performed in a Movement Disorder Centre. 
Some CBS with predominant cognitive symptoms would have been missed 
and it could explain the reason for a SPECT conversion in all our patients. 
Future studies on CBS have to be carried out to clarify in which proportion 
the SPECT could convert to pathological levels. 
FP-CIT SPECT is a useful in vivo measure of SNpc neuronal density 
and it is highly sensitive in detecting subtle changes in early stages of 
degenerative parkinsonisms10, 11 and also years before the clinical 
parkinsonian symptoms onset and it is related to nigral neuronal counts, as 
very recently reported12. Moreover degeneration in SNpc has been 
demonstrated to be faster at the first two years of the disease13. In a recent 
study, Colloby and collaborators described the annual percentage change  
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in striatal (caudate, anterior and posterior putamen) binding in patients with 
Dementia with Lewy Bodies (DLB), Parkinson Disease (PD) and PD with 
dementia (PDD) and healthy age-matched controls. PDD had the largest 
percentage rate of loss (−40.7%), followed by DLB (−12.7%) and PD 
(−11.4%) and the multiple regression analysis revealed that in DLB, the 
annual percentage rate of decline is greater by 28% per year for each 
additional unit of relative FP-CIT uptake in posterior putamen in the initial 
scan14. These data, although obtained in different diseases, are consistent 
with our findings that showed a mean annual percentage change of about 
30%. In a previous study investigating presynaptic nigrostriatal function in 
a large cohort of patient with CBS, we demonstrated that FP-CIT uptake 
does not correlate with disease duration and severity3. We believe that the 
description of these cases further support the hypothesis that 
extrapyramidal features in a number of patients presenting with CBS might 
be due to extra-nigral pathology, including  either at post-synaptic 
nigrostriatal or at cortical level. In conclusion, we speculate that the well-
known heterogeneity of CBD pathology15 might include variants with early 
involvement of the cerebral cortex and sparing SNpc neurons and a 
possible mismatch between pathological cortical and basal involvement. 
 
 
 
  104 
 
REFERENCES 
 
1. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, et al. Neuropathologic 
criteria for Corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61(11): 935–
946. 
2. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet 
Neurol 2004; 3:736–743. 
3. Cilia R, Rossi C, Frosini D, Volterrani D, Siri C, Pagni C, et al. Dopamine Transporter 
SPECT Imaging in Corticobasal Syndrome. Plos One 2011;6(5): e18301. 
4. O’Sullivan SS, Burn DJ, Holton JL, Lees AJ.  Normal dopamine transporter single 
photon-emission CT scan in Corticobasal degeneration. Mov Disord 2008; 23(16): 
2424–2426. 
5. Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, et al. (2005) Voxelwise 
analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple 
system atrophy from idiopathic Parkinson’s disease. Brain 2005; 128: 1605–1612. 
6. Spiegel J, Hellwig D, Mollers M, Behnke S, Jost W, Fassbender K, et al. Transcranial 
sonography and [123I]-FP-CIT SPECT disclose complementary aspects of Parkinson’s 
disease. Brain 2006; 129: 1188–93. 
7. Doran M, du Plessis DG, Enevoldson TP, Fletcher NA, Ghadiali E, et al. Pathological 
heterogeneity of clinically diagnosed Corticobasal degeneration. J Neurol Sci 2003; 
216(1): 127–134. 
8. Hu WT, Rippon GW, Boeve BF, Knopman DS, Petersen RC, et al. Alzheimer’s disease 
and Corticobasal degeneration presenting as Corticobasal syndrome. Mov Disord 2009; 
24(9): 1375–1379. 
9. Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal 
syndrome predictable in life? Mov Disord 2009; 24(11): 1593–1599. 
10. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on 
diagnosis and management of patients with clinically uncertain parkinsonian 
syndromes. Mov Disord 2004;10:1175-1182. 
11. Ceravolo R, Antonini A, Volterrani D, Rossi C, Kiferle L, Frosini D, et al. Predictive 
value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov 
Disord  2008;23: 2049-2054. 
12. Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of 
dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 2012: 
135; 2798–2808. 
13. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of 
progression in Parkinson's disease. Brain 1996; 119: 585-91. 
  105 
 
14. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O’Brien JT. Progression of 
dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with 
and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol 
Imaging 2005; 32:1176–1185. 
15. Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, et al. 
Pathologic heterogeneity in clinically diagnosed Corticobasal degeneration. Neurology 
1999;53:795–800. 
  106 
 
  Chapter VII 
  
Dopamine Transporter expression in patients 
chronically treated with Rotigotine: results from a 
preliminary prospective SPECT study 
 Carlo Rossia, Dario Genovesib, Daniela Frosinia, Chiara Menichettic, Elena Filideib, Duccio Volterranid, Ubaldo Bonuccellia, Roberto Ceravoloa 
 
a. Department of Neuroscience - University of Pisa; b. UO Nuclear Medicine-Fondazione Toscana “G. Monasterio”; c. UO Neurology-Ospedale-ASL1 Città di Castello (PG); d. UO Nuclear Medicine-University of Pisa   
 
Preliminary data – To be submitted 
  107 
 
Abstract  
Background: Neither Ldopa or immediate release dopamine-agonist have 
demonstrated to interfere with FP-CIT SPECT binding. Recently, in order 
to avoid or lower the occurrence of motor complication and to allow a 
more physiologic continuous dopaminergic stimulation longer acting and 
extended release formulations of dopaminergic drugs have been proposed. 
With once-daily application, the patch of Rotigotine matrix provides 
continuous, non-fluctuating plasma drug levels at steady state, resulting in 
continuous and steady plasma and brain levels and striatal dopamine-
receptor stimulation. 
Objective: The aim of this study was to evaluate the effect of chronic 
treatment with Rotigotine on striatal dopamine transporter (DAT) in 
patients with Parkinson's disease (PD) by means of FP-CIT SPECT. 
Methods: In this prospective study, we investigated presynaptic 
nigrostriatal function in 8 de novo patients fulfilling clinical criteria for 
‘‘probable PD’’ (age 59±6.2 years; M/F 5/3) using FP-CIT SPECT before 
and after 3 months of treatment with Rotigotine (mean dose 7.75±1.98 mg).  
For data analysis, specific (left and right caudate, left and right putamen) 
to non-specific (occipital cortex) binding ratios, putamen to caudate ratios 
and asymmetry indexes were calculated. 
Results: During Rotigotine treatment, all patients improved motor 
symptoms (UPDRS III mean score 11.88±2.59 vs 7.63±1.92 on therapy, 
p=0.0022). Striatal FP-CIT levels showed a significant improvement in 
each patient at the follow up scan. Comparisons between the whole group 
before and after treatment showed a significant improvement in FP-CIT 
uptake in both caudate and putamen (p<0.001 in each nucleus). Putamen 
to caudate ratio and asymmetry indexes did not show a significant 
difference before and after treatment. 
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Conclusions: Our results suggest that Rotigotine could affect FP-CIT 
binding and should be withdrawed before SPECT examination. Moreover 
these results could be intriguing in term of potential tolerance for this 
dopamine agonist in PD and in term of potential partial protection of the 
dopamine terminals.  
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1. Introduction  
 
A major challenge of PD research is on means of halting or slowing 
this degenerative process. To date, clinical trials of potential 
neuroprotective drugs have suffered from a lack of markers for the 
underlying PD process. Assessment with clinical scales (such as UPDRS) 
provides an indirect measure of disease progression. The biggest problem 
one faces when using clinical rating scales to assess the efficacy of a 
neuroprotective agent in PD, however, is the confounding symptomatic 
effects due to either the neuroprotective drug itself or dopaminergic agents 
(Ldopa or Dopamine agonists) added over time to maintain patient 
function. A way around this problem may be to use a wash-out or wash-in 
design; however, optimal wash-out or wash-in times of putative 
neuroprotective and dopaminergic drugs are still uncertain. In reality, 
complete wash-out of dopaminergic agents is poorly tolerated by PD 
patients once their condition has become established1. 
Imaging of DAT, using SPECT or PET, has been proved to be a 
useful diagnostic method for the evaluation of patients with movement 
disorders2-4. FP-CIT striatal uptake is reduced in PD, and SPECT results 
correlate with both disease duration and severity5. FP-CIT imaging could 
be a useful tool to monitor PD progression, if its striatal binding is not 
affected by the medication used to treat patients. Previous studies using the 
DAT radioligand β-CIT have demonstrated that antiparkinsonian therapy 
would have no significant effect on its striatal uptake6, 7. More recently 
Schillaci and colleagues found that neither Ldopa affects FP-CIT brain 
imaging8.  Based on these findings indicating that dopamine, Ldopa and 
dopamine agonists in standard dosages do not markedly affect DAT 
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binding, patients are currently submitted to SPECT study without 
withdrawing these drugs9. 
Different studies have used imaging endpoints to investigate PD 
progression in Ldopa treated PD patients10 or the possibility that agonist 
therapy is neuroprotective (relative to L-dopa) in recent-onset Parkinson’s 
disease11-13. The interpretation of their results were contentious. In Elldopa 
study the neuroimaging data suggested that levodopa accelerates the loss of 
nigrostriatal dopamine nerve terminals. Moreover, CALM-PD, REAL-PET 
and PELMOPET studies demonstrated a reduction in loss of striatal β-CIT 
or F-DOPA  in patients treated with agonists compared with those treated 
with L-dopa, and these data might be interpreted as evidence favoring the 
early use of an agonist. However, the validity of the use of functional 
imaging indices as a method of studying PD progression and the validity of 
the interpretation of the these trials’ results have been called into question14, 
15. Some Authors propose that SPECT differences in the different treatment 
group could be due to a pharmacologic effects of chronic dopaminergic 
treatment that could modify the DAT concentration. 
Continuous dopaminergic stimulation is universally accepted to be 
the preferred therapeutic strategy to prevent or postpone dyskinesia in PD. 
Ldopa has a short half-life of 2 hours and causes dyskinesia, whereas 
dopamine receptor agonists usually have a much longer half-life. 
Rotigotine is a non-ergot dopamine D3/D2/D1 receptor agonist with a low 
risk of accumulation due to a half-life of about 5–7 hours. It is rapidly 
metabolized via several cytochromes and shows a low propensity for drug–
drug interaction. Excretion is rapidly provided by renal and hepatic 
pathways. Rotigotine is the only dopamine receptor agonist available as a 
silicone-based transdermal patch. It has been shown that the Rotigotine 
patch provides constant delivery. There is good evidence that once-daily 
  111 
 
patch usage provides patients with constant dopaminergic stimulation, and 
that patches are of equal potency to other oral non-ergot derivatives such as 
ropinirole and pramipexole. The patch of Rotigotine matrix provides 
continuous, non-fluctuating plasma drug levels at steady state, resulting in 
continuous and steady plasma and brain levels and striatal dopamine-
receptor stimulation.  
Regarding its peculiar pharmacokinetic properties, in the current 
study we evaluated whether chronic treatment with Rotigotine patch could 
regulate DAT expression in patients with PD by means of FP-CIT SPECT. 
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2. Methods  
 
2.1 Study design  
In this prospective study a group of drug-naïve PD outpatients were 
recruited in the Movement Disorder Center – Department of Neuroscience 
– University of Pisa. The subjects were enrolled between December 2010 
and December 2011. All patients underwent to two clinical and SPECT 
evaluation, before and after a three months Rotigotine treatment. The study 
was approved by the Ethics Committees of the our institution. Subjects’ 
consent was obtained according to the Declaration of Helsinki. 
 
2.2 Patients 
Eight outpatients with clinical diagnosis of “probable PD” according to 
UKBB criteria were recruited. We excluded those patients with exposure to 
typical neuroleptics, those with brain MRI evidence of moderate-to-severe 
vascular abnormalities, space-occupying lesions or normal pressure 
hydrocephalus and those who presented a history of depression, impulse 
control disorder, hallucinations or dementia. For this reason at the baseline  
visit patients underwent to an accurate anamnestic history and to cognitive 
scales administration (the patient was excluded if MMSE was less than 
26/30).  Motor function assessment in PD patients included the Hoehn and 
Yahr stage (H&Y) and the Unified Parkinson Disease Rating Scale motor 
score (UPDRS III) assessed in the morning before the Rotigotine treatment 
(baseline) and while on their current therapy (follow up visit). When the 
patients were recruited and the Baseline SPECT scan was performed, 
Rotigotine was up-titrated to their optimal dose in weekly increments of 2 
mg/24 h to a maximum dose of 8 mg/24 h (maximum titration period 30 
days). Back-titration was permitted during the titration period, followed by 
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immediate initiation of the maintenance phase. The optimal dose was 
defined following discussion between the patient and the investigator, 
taking into account the potential for improvement of disease symptoms and 
the patient’s AE profile. In order to minimize treatment bias which could 
interfere with DAT imaging no other medical treatment was admitted.  
 
2.3 FP-CIT SPECT 
SPECT studies were carried out at the Nuclear Medicine, Fondazione 
Toscana “G. Monasterio – CNR – Pisa – Italy. Intravenous administration 
of 185MBq of 123I-2b-carbometoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) 
nortropane (FPCIT) (DaTscanH, GE Healthcare) was performed 30-40 min 
after thyroid blockade in all subjects. Brain SPECT was performed 3-4 
hours later by means of a dedicated dual-head gamma camera (GE-
Millennium MG, Haifa, Israel) equipped with high resolution low energy 
parallel holes collimators, matrix size 128x128, radius of rotation 13–15 
cm, 120–128 projections over a 360° circular orbit. The overall scanning 
time for each patient was 30 to 45 minutes. Brain sections were obtained by 
applying an iterative algorithm (OS-EM, 2–4 iterations and 8–15 subsets) 
on projection data and a 3D postfilter (Butterworth, order 5, cut-off 0.3 Ny) 
and attenuation correction (Chang method, m = 0.12 cm21). Transaxial 
data were reoriented along the fronto-occipital line. Usually five to eight 
slices were summed in order to include the basal ganglia.  Semiquantitative 
analysis was performed using a software developed by GE Healthcare on a 
GE Xeleris workstation. The software used five pre-defined fixed ROIs 
which were manually positioned over the caudates, the putamen nuclei and 
the occipital cortex on reoriented axial data which were summed to obtain 
an overall slice of 15 mm thick, including almost the whole striatum nuclei 
(Figure 1). Mean counts calculated within caudate and putamen nuclei 
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were divided by mean occipital counts obtaining striatal/to non-specific 
binding ratios for each nucleus. Asymmetry index (AI) in putamen, caudate 
and striatum was calculated with the following formula: AI = (ipsilateral–
contralateral)/(ipsilateral+contralateral)x100.  A Putamen / Caudate index 
was calculated using the following formula: PCI = (putamen - 
caudate)/(putamen +caudate) x 10016. 
 The Semiquantitative analysis was performed at the end of the study 
on both SPECT scan with the Nuclear Medicine Doctor blinded to the 
patients and to the follow-up/baseline SPECT.  
Paired t tests were used for comparison to baseline values. The 
clinical data was similarly analyzed. 
 
 
Figure 1. ROI analysis – Predefined fixed ROIs on both caudate, 
putamen and occipital cortex (SPECT from patient 1). 
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3. Results 
 
3.1 Patients 
Cohort characteristics are summarized in the Table 1. The mean age was 
59±6.2 years, Rotigotine mean dose was7.75±1.98 mg. All patients showed 
a significant motor improvement (UPDRS baseline 11.88±2.59; follow up 
7.63±1.92, p=0.0022). 
 
 
Table 1. Demographic and clinical characteristics of the cohort. * 
UPDRS III is significantly improved (p=0.0022) between baseline and 
follow-up evaluation (two tails paired t test). 
 
No serious adverse events were reported. Mild somnolence was reported in 
two cases. 
 
3.2 SPECT analyses 
Striatal FP-CIT levels showed a significant improvement in each nucleus of 
patient at the follow up scan (See Figure 2 and 3). Comparisons between 
the whole group before and after treatment showed a significant 
improvement in FP-CIT uptake in both caudate and putamen (p<0.001 in 
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each nucleus – see table 2) with a mean increase in FPCIT uptake of +13% 
for caudate nucleus and 17% for putamen. Putamen to caudate ratio and 
asymmetry indexes did not show a significant difference before and after 
treatment. 
 
 
 
 
 
 
Figure 2. Example of Case 1 – At left qualitative SPECT analyses at 
baseline (top) and follow up (bottom). At the right Semiquantitative data 
between baseline (left) and follow up (right). 
 
 
 
 
 
Table 2. Mean semi-quantitative uptake in caudate and putamen and 
caudate/putamen ration in the cohort of patients (two tails paired t test). 
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Figure 2. Difference in semi-quantitative FP-CIT uptake between each 
nucleus (putamen dx, putamen sx, caudate dx and caudate sx) between 
baseline and follow up. 
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4. Discussion  
 
The role of neuroimaging techniques, including SPECT, in assessing 
neuroprotective therapies in PD is still under debate; however, to be useful 
for this purpose, imaging should not be influenced by the drugs used to 
treat patients. In our study we found that DAT is significantly influenced 
by a subacute (mean of three months) treatment with rotigotine. This result 
is discordant with previous studies with other dopamine agonists and 
Ldopa where in most cases no change were found6-8 and  in only one case a 
reduction in DAT expression was postulated. The small sample size in our 
cohort must be considered, however all patients showed a significant FP-
CIT uptake increase in both nucleus and in both side (a mean of +13% in 
caudate and +17% in putamen). There are different explanation that could 
be proposed: the difference may be due to pharmacokinetic properties of 
rotigotine (absence of first-pass effect, possible P450 cytochromes 
interaction between rotigotine and radioligand FP-CIT, the patch provides 
sustained therapeutic plasma drug  levels whereas oral administration does 
not results in stable 24-hour blood concentration) or to pharmachodynamic 
properties (Rotigotine receptor affinity may be partially different to the 
others dopaminergic treatments). Lastly, the preliminary results of our 
study may be the first demonstration of a DAT regulation in response to 
dopamine agonist treatment with intriguing consequences in terms of 
neuroprotective/neurotoxic effects or disease modifying effect (especially 
in motor complication development) of dopaminergic treatment in PD.  
The findings of previous PET and SPECT studies in early PD 
patients after treatment with levodopa or dopamine agonists are discordant.  
The short term effect of pramipexole on DAT imaging in a small cohort of 
early PD patients was analyzed by Guttman and colleagues17. Comparison 
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was made to carbidopa/levodopa treatment as well as placebo. Striatal DAT 
was significantly down-regulated by levodopa therapy in this 6-week 
study17; pramipexole treatment also reduced DAT binding, but the effect 
was substantially less. This investigation attests to the potential for 
dopamine-active drugs to regulate DAT. Another dopamine agonist, 
pergolide, was assessed in a similar study of PD patients7. Adjunctive 
treatment for 6 weeks resulted in a trend toward increased 123I-β-CIT 
uptake, which reversed after pergolide washout. The number of patients 
with PD in this study was also small (N° 12), and a more robust effect 
might have been seen with more subjects. These investigators raised a 
caveat about the possible pharmacologic influence of dopamine agonist 
therapy on DAT regulation and 123I-β-CIT uptake7. Recently Ldopa has 
been demonstrated to not induce modifications of DAT expression 
detectable by either SPECT or DAT binding autoradiography in an animal 
model of MPTP-treated monkeys18. This result is in agreement with three  
short-term investigations in Ldopa treated PD patients6, 8, 19. These trials 
assessed seven to fifteen patients. The short-term trials that failed to 
document changes in DAT imaging associated with levodopa6, 8, 19 or 
dopamine agonists therapy had notably small numbers. These short-term 
trials may not have been adequately powered to detect the relatively small 
differences in radioligand uptake found in the long-term trial13. The large, 
multicenter trial conducted by the Parkinson Study Group, analyzed the 
rate of decline of imaged striatal 123I-β-CIT with chronic pramipexole vs 
carbidopa/levodopa treatment13. Specifically, patients randomized to 
pramipexole had significantly less decline in striatal 123I-β-CIT uptake (less 
decline in DAT levels) after 2, 3, and 4 years of treatment. This result 
suggested a favorable effect of pramipexole rather than a detrimental effect 
of levodopa treatment. The investigators correctly recognized that a simple 
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pharmacologic effect on DAT expression, turnover, or function might be 
responsible for their findings. Their primary argument against this was that 
no differences were present at 10 weeks of treatment, comparing seven 
pramipexole-treated patients to six treated with carbidopa/levodopa13.  
Considering our and previous studies results, a major issue is what 
we are measuring with DAT imaging. Indeed, despite DAT is related to 
nigral neuronal loss, measuring DAT is not the same of measuring nigral 
neuronal cell loss.  If DAT expression per nigrostriatal neuron is stable, 
then any reduction of DAT-radiotracer uptake must indicate fewer 
nigrostriatal neurons. DAT is responsible for removing released dopamine 
from synaptic regions and is critical for proper modulation of dopaminergic 
neurotransmission. It is a highly regulated protein with a high turnover rate; 
in rats, DAT has a half-life of only 2 days20. DAT expression varies with 
factors influencing dopaminergic neurotransmission. In patients with PD, 
the reduced brain dopamine levels are compensated by down-regulation of 
DAT21 similar to what occurs in animal models22. DAT mRNA levels per 
pigmented nigral neuron are reduced in PD23-25 reflective of compensatory 
down-regulation. With this potential for regulation of DAT expression, it 
follows that changes in DAT imaging could simply reflect a pharmacologic 
effect on this regulation; i.e., a drug-induced alteration of DAT expression 
per neuron. Dopamine agonist drugs have prominent pharmacologic effects 
on DAT regulation. In rats, the half-life, production, and degradation of 
DAT is markedly influenced by dopamine agonist administration20. 
Dopamine D2 agonist drugs up-regulate DAT function in vitro26, 27. In fact, 
it seems that any drug that affects dopaminergic neurotransmission 
potentially can influence DAT regulation. Up-regulation of striatal DAT 
has also been documented with amantadine28, which facilitates dopamine 
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release29.  For these reason we chose a population drug-naïve and any other 
treatment apart from rotigotine was not admitted.  
The different receptor pharmacology of non ergot dopamine agonists 
vs dopamine  generated from levodopa may be relevant. In contrast to 
rotigotine, pramipexole and ropinirole, dopamine is a potent agonist at D1 
and D2 receptors.  D1 receptor stimulation activates adenylate cyclase, 
generating cAMP, whereas D2 stimulation has the opposite effect30. DAT 
is regulated by phosphorylation31-35. D1-stimulated cAMP activates protein 
kinases (especially protein kinase C), which phosphorylate DAT, resulting 
in inhibition of DAT function and expression and causing sequestration and 
internalization of DAT protein from cell membranes35. Conversely, D2 
agonists up-regulate DAT, which may be mediated by protein kinase A27. 
Thus, D1 stimulation potentially has a negative effect on neuronal DAT 
expression and D2 the opposite. The actual effects, however, depend upon 
which receptor subtypes colocalize with DAT in the specific brain regions. 
In addition to different effects on receptor subtypes, pergolide, pramipexole 
and ropinirole differ from Ldopa in terms of duration of action and potency 
and rotigotine differs from both Ldopa and other dopamine agonists by 
reason of its peculiar way of administration.  In order to verify which 
mechanism could be responsible of our results an extension of the study 
with 3 other groups of patients (one treated with ropinirole extended 
release, one with pramipexole extended release and the last with rotigotine 
administered only 16 hours per day) will be performed.  
DAT up-regulation have functional consequences. First, this 
mechanism could be responsible for a tolerance mechanism in patients 
treated with rotigotine with a less motor benefit because of a less dopamine 
stimulation on post-synaptic dopamine receptor . This could be the 
rationale for the less symptomatic effects of dopamine agonists compared 
  122 
 
to Ldopa. It’s nevertheless well demonstrated that rotigotine treatment is 
similarly efficacious to other dopamine-agonists in different stages of PD 
and recently the extension of these studies showed a long-lasting motor 
benefit in rotigotine-treated patients36-43. The second major point is 
however the possible effect in term of disease modifying in patients treated 
with dopamine agonists.   Increased DAT expression per neuron should 
result in more rapid clearance of dopamine from the region of the synapse. 
One might predict that this should result in less dyskinesia. Results from a 
multi-tracer work showed a significant positive correlation between DAT 
density and DA storage capacity (or negative correlation between DAT 
density and DA turnover) in patients with moderate PD44. This finding 
implies that the relation between DAT density and DA turnover is not only 
a reflection of the degree of dopaminergic terminal loss, but may indeed 
have functional significance. It was previously observed that, in the 
putamen, DA turnover increases considerably early in the disease, 
becoming greater than that in the caudate, whereas in the normal state, the 
reverse appears to be true45-47. The observation that a decrease in DAT 
levels is also present in early disease and even in a pre-symptomatic stage 
might suggest a causative relation between the two, whereby a decrease in 
DAT expression might reduce the ability to take DA back up into 
presynaptic terminals, thus leaving it exposed to enzymatic degradation in 
the synapse and consequent clearance from the brain. A larger change in 
synaptic DA levels was observed to be associated with lower DAT 
expression, likely as a result of reduced DAT-mediated DA clearance from 
the synapse. The significant relation between effective dopamine 
distribution volume and DA variation may be interpreted to provide the 
final link, whereby higher turnover, and thus DA clearance out of the brain, 
is associated with increased relative changes in synaptic DA, whereas 
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lower turnover is associated with greater DAT levels, and thus DA 
recycling. Reduced reuptake capacity, aimed at maintaining relatively 
greater synaptic DA levels, may thus indeed serve as a compensatory 
mechanism in early disease, where the DA storage capacity and DA levels 
are still relatively preserved. As disease progresses, however, the DA 
storage capacity decreases, causing any exogenously derived DA to be 
immediately released into the synapse; in this scenario, DAT mediated 
reuptake would serve to bring DA back into the presynaptic terminals, 
where it can be repackaged into the vesicles and subsequently reutilized. 
DAT would thus serve as a modulator of synaptic DA levels, preventing 
extreme highs and lows. Combining these observations with the prevailing 
view that oscillations in synaptic DA and an increase in turnover are linked 
to the occurrence of motor complications suggests that DAT levels and/or 
function might indeed play a crucial role in the predisposition to and 
occurrence of motor complications. Considering this scenario, dopamine 
agonists and rotigotine in particular could determine a re-normalization of 
DAT level with an opposite size in respect to compensatory mechanisms 
and finally reduce the risk of dyskinesia development. This is in agreement 
with the results of our study. In details the uptake increase was higher in 
putamen than in caudate (17% versus 13%) and just putamen represents the 
nucleus in which this compensatory mechanism has been reported. 
Up-regulating DAT (more DAT per neuron) could actually have also 
deleterious consequences for surviving dopaminergic cells, based on the 
potential for DAT to transport toxins into dopaminergic neurons48. This 
has been demonstrated with known nigral neurotoxins, such as 6-
hydroxydopamine and MPTP, which depend upon DAT for their selective 
toxicity48. In laboratory studies, up-regulation of DAT increases the 
toxicity of each and under-expression is protective. In humans, the regional 
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vulnerability of dopaminergic neurons to the PD neurodegenerative process 
is directly correlated with the levels of DAT expression48. Within PD 
substantia nigra, healthy, surviving nigral cells express lower levels of 
DAT than nigral neurons from age- and sex-matched control brains48. On 
the contrary a recent study found that rotigotine treatment partially protects 
from MPTP toxicity in a progressive macaque model of Parkinson’s 
disease49. 
 
 
5. Conclusions  
Our results suggest that Rotigotine could affect FP-CIT binding and should 
be withdrawed before SPECT examination. The underlying mechanism of 
rotigotine influence on FP-CIT uptake may be due to pharmacokinetic or 
pharmachodynamic mechanisms. A possible interaction in hepatic 
metabolism between FP-CIT and rotigotine must be exluded. The linear 
kinetic or the receptor affinity are probably the cause of an over-expression 
of DAT. Anyway, a DAT over-expression has functional consequences in 
terms of symptomatic efficacy and possible disease modifying effect. 
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